Citation Report
List of articles citing

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

DOI: 10.1016/j.cell.2020.02.052
Cell, 2020, 181, 271-280.e8.

#	Paper	IF	Citations
2199	The good, the bad, and the ugly in chemical and biological data for machine learning. **2019**, 32-33, 3-8		10
2198	Pediatric Endocrinology in the Time of the COVID-19 Pandemic. **2019**, 92, 345-346		2
2197	Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. **2020**, 22, 119-126		5
2196	Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy. **2020**, 7, ofaa424		4
2195	Predicting susceptibility to SARS-CoV-2 infection based on structural differences in ACE2 across species. **2020**, 34, 15946-15960		24
2194	A review of severe acute respiratory syndrome coronavirus 2 infection in the reproductive system. **2020**, 83, 895-897		10
2193	Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. **2020**, 54, 438-450		13
2192	Expression of SARS-CoV-2 receptor and the protease suggests susceptibility of the human embryo in the first trimester. **2020**, 10, 200162		43
2191	Special issue on COVID-19 and pregnancy: Consequences for maternal and neonatal health. **2020**, 84, e13354		2
2190	Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. **2020**, 50, 1483-1491		11
2189	The COVID-19 pandemic: a global health crisis. **2020**, 52, 549-557		93
2188	Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. **2020**, 76, 1526-1536		26
2187	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices. **2020**, 76, 1350-1367		36
2186	COVID-19 pandemic: current knowledge about the role of pets and other animals in disease transmission. **2020**, 17, 143		36
2185	How COVID-19 induces cytokine storm with high mortality. **2020**, 40, 37		238
2184	In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. **2020**, 15, e0240149		31
2183	The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. **2020**, 11, 595739		46

2182	COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention. **2020**, 11, 956	20
2181	Iran's Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials. **2020**, 8, 551889	10
2180	The management of allergic diseases in children during the SARS-CoV-2 pandemic. **2020**, 7, 153-161	0
2179	[Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. **2020**, 69, 247-254	5
2178	The prophylaxis and treatment potential of supplements for COVID-19. **2020**, 887, 173530	29
2177	SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. **2020**, 146, 111769	82
2176	Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review. **2020** , 24, 594	24
2175	Drug Weaponry to Fight Against SARS-CoV-2. **2020**, 7, 204	2
2174	Endothelial Cell Contributions to COVID-19. **2020**, 9,	12
2173	Angiotensin-converting enzyme 2: A protective factor in regulating disease virulence of SARS-COV-2. **2020**, 72, 2533-2545	8
2172	Assessing the SARS-CoV-2 threat to wildlife: Potential risk to a broad range of mammals. **2020**, 18, 223-234	13
2171	SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors. **2020**, 289, 198154	10
2170	The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis. **2020**, 11, 574541	30
2169	Differential Expression of Viral Transcripts From Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its Implications for Case Severity. **2020**, 11, 603509	20
2168	Host Immune Response Driving SARS-CoV-2 Evolution. **2020**, 12,	42
2167	A dissection of SARS-CoV2 with clinical implications (Review). **2020**, 46, 489-508	24
2166	Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). **2020**, 16, 2906-2923	20
2165	Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?. **2020**, 35, 1725	2

2164	Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2. **2020**, 113, 572-578	2
2163	Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. **2021**, 46, 382-391	32
2162	Androgen deprivation and SARS-CoV-2 in men with prostate cancer. **2020**, 31, 1417-1418	17
2161	Does androgen deprivation therapy protect against severe complications from COVID-19?. **2020**, 31, 1419-1420	41
2160	Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19. **2020**, 132, 110886	27
2159	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. **2020**, 18, 2100-2106	4
2158	The Scientific Foundation of Chinese Herbal Medicine against COVID-19. **2020**, 6, 1099-1107	12
2157	Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment. **2020**, 6, e05278	15
2156	Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain. **2020**, 21, 100451	11
2155	Immunotherapeutic approaches to curtail COVID-19. **2020**, 88, 106924	29
2154	Age-Related Differences in Immunological Responses to SARS-CoV-2. **2020**, 8, 3251-3258	26
2153	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. **2020**, 131, 104611	38
2152	The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET. **2020**, 28, 1218-1224.e4	62
2151	Tissue-specific and interferon-inducible expression of nonfunctional ACE2 through endogenous retroelement co-option. **2020**, 52, 1294-1302	54
2150	The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. **2020**, 10, 16944	50
2149	Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity. **2020**, 295, 17986-17996	70
2148	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. **2020**, 2, e0207	8
2147	The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. **2020**, 76, 397-406	9

2146	Therapeutic Potential of B-1a Cells in COVID-19. **2020**, 54, 586-594	10
2145	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. **2020**, 13, 255-260	12
2144	Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients. **2020**, 11, 437	28
2143	Syncytia formation by SARS-CoV-2-infected cells. **2020**, 39, e106267	167
2142	COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes. **2020**, 8, 593455	13
2141	Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study. **2020**, 11, 560209	11
2140	Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19. **2020**, 11, 555039	47
2139	Pathophysiology of Cardiovascular Complications in COVID-19. **2020**, 11, 575600	21
2138	Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study. **2020**, 25,	16
2137	Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients. **2020**, 16, 3028-3036	8
2136	Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. **2020**, 50, 2013-2024	35
2135	Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer. **2020**, 9, 945-947	0
2134	ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. **2020**, 11, 576745	98
2133	Research Progress of Genetic Structure, Pathogenic Mechanism, Clinical Characteristics, and Potential Treatments of Coronavirus Disease 2019. **2020**, 11, 1327	3
2132	Stem Cells Secretome from Oral Tissue Could Represent a Promising Therapeutic Approach in COVID-19-Disease?. **2020**, 21,	2
2131	New SARS-CoV-2 Infection Detected in an Italian Pet Cat by RT-qPCR from Deep Pharyngeal Swab. **2020**, 9,	25
2130	Co-expression of peripheral olfactory receptors with SARS-CoV-2 infection mediators: Potential implications beyond loss of smell as a COVID-19 symptom. **2020**, 46, 949-956	24
2129	Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System. **2020**, 22, 37	38

2128	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. **2020**, 182, 114225		40
2127	The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. **2020**, 179, 85-100		47
2126	Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. **2020**, 131, 110622		89
2125	Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test. **2020**, 2, 226-231		33
2124	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell*, **2020**, 183, 169-184.e13	56.2	221
2123	Effects of COVID-19 on the Nervous System. *Cell*, **2020**, 183, 16-27.e1	56.2	268
2122	On the genetics and immunopathogenesis of COVID-19. **2020**, 220, 108591		22
2121	Potential use of polyphenols in the battle against COVID-19. **2020**, 32, 149-155		52
2120	COVID-19 pathways for brain and heart injury in comorbidity patients: A role of medical imaging and artificial intelligence-based COVID severity classification: A review. **2020**, 124, 103960		44
2119	Repurposing anticancer drugs for the management of COVID-19. **2020**, 141, 40-61		30
2118	Azithromycin: The First Broad-spectrum Therapeutic. **2020**, 207, 112739		25
2117	Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. **2020**, 887, 173545		23
2116	COVID-19 associated complications and potential therapeutic targets. **2020**, 886, 173548		10
2115	Curcumin, a traditional spice component, can hold the promise against COVID-19?. **2020**, 886, 173551		52
2114	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. **2020**, 887, 173561		8
2113	Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. **2020**, 762, 145102		76
2112	Nucleic acid-based therapy for coronavirus disease 2019. **2020**, 6, e05007		17
2111	COVID-19 and Microvascular Disease: Pathophysiology of SARS-CoV-2 Infection With Focus on the Renin-Angiotensin System. **2020**, 29, 1596-1602		22

2110	Biosensor and molecular-based methods for the detection of human coronaviruses: A review. **2020**, 54, 101662	22
2109	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. **2020**, 79, 153333	31
2108	Antiviral properties of placental growth factors: A novel therapeutic approach for COVID-19 treatment. **2020**, 99, 117-130	3
2107	COVID-19 Vaccine: A comprehensive status report. **2020**, 288, 198114	380
2106	Techniques and Strategies for Potential Protein Target Discovery and Active Pharmaceutical Molecule Screening in a Pandemic. **2020**, 19, 4242-4258	5
2105	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. **2020**, 15, 3699-3715	113
2104	Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. **2020**, 9, 2245-2255	73
2103	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. **2020**, 50, 1313-1324	41
2102	COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission. **2020**, 59, 1409-1410	1
2101	Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations. **2020**, 5,	17
2100	COVID-19 and Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research Questions. **2020**, 40, 2586-2597	44
2099	Severe COVID-19: what have we learned with the immunopathogenesis?. **2020**, 60, 50	29
2098	Unraveling the Epidemiology, Geographical Distribution, and Genomic Evolution of Potentially Lethal Coronaviruses (SARS, MERS, and SARS CoV-2). **2020**, 10, 499	10
2097	Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. **2020**, 11, 570122	106
2096	Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay. **2020**, 11, 2020	26
2095	Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence. **2020**, 11, 579886	14
2094	Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. **2020**, 9,	9
2093	Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors. **2020** , 13,	8

2092	An investigation into the molecular basis of cancer comorbidities in coronavirus infection. **2020**, 10, 2363-2374	5
2091	ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. **2020**, 131, 110678	98
2090	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. **2020**, 32, 537-547.e3	81
2089	The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. **2020**, 18, 2438-2444	18
2088	Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms. **2020**, 25, 2076-2079	19
2087	Acute Kidney Injury in COVID-19: The Chinese Experience. **2020**, 40, 430-442	17
2086	COVID-19 in the Pediatric Population-Review and Current Evidence. **2020**, 22, 29	12
2085	Druggable targets from coronaviruses for designing new antiviral drugs. **2020**, 28, 115745	10
2084	Activation of the SARS-CoV-2 Receptor Ace2 through JAK/STAT-Dependent Enhancers during Pregnancy. **2020**, 32, 108199	13
2083	Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity. **2020**, 18, 2573-2582	26
2082	Chloroquine against malaria, cancers and viral diseases. **2020**, 25, 2012-2012	23
2081	Cardiac inflammation in COVID-19: Lessons from heart failure. **2020**, 260, 118482	40
2080	The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydrate-carbohydrate interactions. **2020**, 144, 110155	30
2079	Thermodynamic equilibrium dose-response models for MERS-CoV infection reveal a potential protective role of human lung mucus but not for SARS-CoV-2. **2020**, 16, 100140	12
2078	Structural and functional modelling of SARS-CoV-2 entry in animal models. **2020**, 10, 15917	37
2077	Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome. **2020**, 20, 1087-1097	12
2076	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its effect on gametogenesis and early pregnancy. **2020**, 84, e13351	13
2075	ACEIs and ARBs and Their Correlation with COVID-19: A Review. **2020**, 13, 3217-3224	15

2074	COVID-19: Significance of antibodies. **2020**, 28, 287-297		13
2073	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. **2020**, 11, 1224		17
2072	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell*, **2020**, 183, 1024-1042.e21	56.2	601
2071	A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors. **2020**, 32, 108175		118
2070	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. **2021**, 8, 385-400		18
2069	Identification of twenty-five mutations in surface glycoprotein (Spike) of SARS-CoV-2 among Indian isolates and their impact on protein dynamics. **2020**, 21, 100891		10
2068	Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. **2020**, 20, 100407		40
2067	The role of Interleukin-4 in COVID-19 associated male infertility - A hypothesis. **2020**, 142, 103213		16
2066	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. **2020**, 262, 118496		3
2065	Environmental pollutant exposure can exacerbate COVID-19 neurologic symptoms. **2020**, 144, 110136		2
2064	Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients. **2020**, 144, 110271		29
2063	Multivalent nanomedicines to treat COVID-19: A slow train coming. **2020**, 35, 100962		22
2062	A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection. **2020**, 101, 13-29		69
2061	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. **2020**, 41, 4037-4046		52
2060	Investigation of the psychological status of suspected patients during the Coronavirus disease 2019 epidemic. **2020**, 99, e22260		6
2059	Pathophysiology of coronavirus disease 2019 for wound care professionals. **2020**, 17, 1935-1940		6
2058	Antiviral Drug Discovery To Address the COVID-19 Pandemic. **2020**, 11,		5
2057	Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology. **2020**, 13, 15		8

2056	Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. **2020**, 11, 2163	17
2055	Familial Mediterranean Fever and COVID-19: Friends or Foes?. **2020**, 11, 574593	7
2054	Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. **2020**, 11, 585647	40
2053	The Potential of Antiviral Peptides as COVID-19 Therapeutics. **2020**, 11, 575444	31
2052	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. **2020**, 12,	17
2051	SARS-CoV-2-Related Kidney Injury: Current Concern and Challenges. **2020**, 2, 1-10	4
2050	Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. **2020**, 28, 586-601.e6	192
2049	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. **2020**, 887, 173568	2
2048	Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies. **2020**, 260, 118313	27
2047	COVID-19 in children: what did we learn from the first wave?. **2020**, 30, 438-443	6
2046	anti-HCoV: A web resource to collect natural compounds against human coronaviruses. **2020**, 106, 1-11	2
2045	Transcription-based drug repurposing for COVID-19. **2020**, 290, 198176	4
2044	Identifying pathophysiological bases of disease in COVID-19. **2020**, 5, 15	4
2043	Metabolic impact of weight loss induced reduction of adipose ACE-2 - Potential implication in COVID-19 infections?. **2020**, 113, 154401	14
2042	Predictive indicators of severe COVID-19 independent of comorbidities and advanced age: a nested case-control study. **2020**, 148, e255	12
2041	A high-stringency blueprint of the human proteome. **2020**, 11, 5301	59
2040	Potential Therapeutic Options for COVID-19. **2020**, 2, 89-95	
2039	COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?. **2020**, 131, 1324-1333	34

2038	The Potential Intermediate Hosts for SARS-CoV-2. **2020**, 11, 580137		55
2037	Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. **2020**, 12,		29
2036	Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?. **2021**, 66, 2855-2864		6
2035	Emergence and Evolution of Olfactory and Gustatory Symptoms in Patients with COVID-19 in the Outpatient Setting. **2020**, 1-7		4
2034	A Crowned Killer's R□um□Genome, Structure, Receptors, and Origin of SARS-CoV-2. **2020**, 35, 673-684		7
2033	Cancerona: Challenges of Cancer Management in Times of COVID-19 Pandemic. **2020**, 2, 1-10		1
2032	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell*, **2020**, 183, 1058-1069.e19	56.2	182
2031	Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. **2020**, 14, 2039-2041		17
2030	Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction. **2020**, 27, 890-904.e8		119
2029	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. **2020**, 1, 100126		134
2028	The COVID-19 Pandemic from a Human Genetic Perspective. **2020**, 19, 4374-4379		1
2027	Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. **2020**, 52, 1283-1293		132
2026	Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. **2020**, 117, 28336-28343		77
2025	Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. **2020**, 9, 2433-2445		86
2024	Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. **2020**, 116, 2197-2206		62
2023	ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects. **2020**, 161, 2494-2501		42
2022	Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. **2020**, 370, 856-860		809
2021	Neuropilin-1 is a host factor for SARS-CoV-2 infection. **2020**, 370, 861-865		568

2020	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. **2021**, 39, 119-139	36
2019	Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. **2020**, 17, 154	38
2018	Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection. **2020**, 40, 39	24
2017	A comprehensive review about SARS-CoV-2. **2020**, 15, 625-648	37
2016	Analysis of the Spectrum of Variation Suggests a Possible Influence of Rare and Common Variants on Susceptibility to COVID-19 and Severity of Outcome. **2020**, 11, 551220	12
2015	Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor. **2020**, 8,	9
2014	Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions. **2020**, 6, 350-360	34
2013	Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. **2020**, 50, 2025-2040	111
2012	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?. **2020**, 8, e00666	8
2011	Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. **2020**, 41, 3437-3470	74
2010	SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations. **2020**, 31, 1-13	13
2009	First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient. **2020**, 31, 1418-1419	14
2008	Genetic and hormonal influence on SARS-CoV-2-infection susceptibility: Re: The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality. **2020**, 31, 1584-1585	1
2007	An immunoinformatics study on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates. **2020**, 6, e04865	5
2006	2020 update on human coronaviruses: One health, one world. **2020**, 8, 100043	12
2005	Síndrome inflamatorio multisistémico en niños con COVID-19: una visión desde la reumatología. **2020**, 28, 289-289	
2004	Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. **2020**, 27, 905-919.e10	92
2003	Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity. **2020**, 2, 100023	19

2002	Expression of SARS-CoV-2 entry factors in lung epithelial stem cells and its potential implications for COVID-19. **2020**, 10, 17772	27
2001	Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. **2020**, 10, 17698	58
2000	A systematic review of etiology, epidemiology, clinical manifestations, image findings, and medication of 2019 Corona Virus Disease-19 in Wuhan, China. **2020**, 99, e22688	3
1999	Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. **2020**, 13, 1178633720962935	16
1998	Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology. **2020**, 13, 17	9
1997	How to boost the immune defence prior to respiratory virus infections with the special focus on coronavirus infections. **2020**, 12, 47	9
1996	The epigenetic implication in coronavirus infection and therapy. **2020**, 12, 156	29
1995	The Role of the Ocular Tissue in SARS-CoV-2 Transmission. **2020**, 14, 3017-3024	12
1994	Identifying Pathways and Networks Associated With the SARS-CoV-2 Cell Receptor ACE2 Based on Gene Expression Profiles in Normal and SARS-CoV-2-Infected Human Tissues. **2020**, 7, 568954	14
1993	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. **2020**, 11, 562777	7
1992	Innate and adaptive immune responses against coronavirus. **2020**, 132, 110859	34
1991	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. **2020**, 33, 108322	35
1990	Quantitative assessment of olfactory dysfunction accurately detects asymptomatic COVID-19 carriers. **2020**, 28, 100575	24
1989	Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications. **2021**, 7, 1441-1451	32
1988	Antiviral Peptides as Promising Therapeutics against SARS-CoV-2. **2020**, 124, 9785-9792	33
1987	Targeting Proteases for Treating COVID-19. **2020**, 19, 4316-4326	36
1986	Chest CT in COVID-19: What the Radiologist Needs to Know. **2020**, 40, 1848-1865	135
1985	Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. **2020**, 14, 40	61

1984	Finding potent inhibitors for COVID-19 main protease (M): an approach using SARS-CoV-3CL protease inhibitors for combating CORONA. **2020**, 1-12	12
1983	Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors. **2020**, 2020, 8198963	23
1982	Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis. **2020**, 16, e1008235	5
1981	Advances in Computational Intelligence. **2020**,	
1980	[COVID-19 and venous thromboembolism]. **2020**, 69, 370-375	2
1979	Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. **2020**, 52, 1383-1389	27
1978	Expression profiles of the SARS-CoV-2 host invasion genes in nasopharyngeal and oropharyngeal swabs of COVID-19 patients. **2020**, 6, e05143	8
1977	An aberrant STAT pathway is central to COVID-19. **2020**, 27, 3209-3225	95
1976	Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. **2020**, 5, 1439-1448	76
1975	Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. **2020**, 10, 200174	10
1974	Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown. **2021**, 28, 3503-3516	13
1973	Repurposing existing drugs for COVID-19: an endocrinology perspective. **2020**, 20, 149	28
1972	T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis. **2020**, 11, 589380	69
1971	Neurologist□ role during the SARS-COV-2 pandemic. **2020**, 29, 133-140	
1970	Catch me if you can: SARS-CoV-2 detection in brains of deceased patients with COVID-19. **2020**, 19, 883-884	6
1969	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. **2020**, 104, 104326	12
1968	Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. **2020**, 43, 399-413	25
1967	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. **2020**, 33, 108254	107

1966	Neurological complications in a predominantly African American sample of COVID-19 predict worse outcomes during hospitalization. **2020**, 197, 106173	20
1965	COVID-19 and the kidney: A matter of concern. **2020**, 10, 165-168	6
1964	Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract. **2020**, 60, 102976	94
1963	Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. **2020**, 889, 173634	21
1962	Furin: A Potential Therapeutic Target for COVID-19. **2020**, 23, 101642	86
1961	Study presence of COVID-19 (SARS-CoV-2) in the sweat of patients infected with Covid-19. **2020**, 149, 104556	12
1960	Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections. **2020**, 44, 2335-2338	21
1959	Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. **2020**, 1-10	7
1958	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). **2020**, 7, 585866	35
1957	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. **2020**, 99, 1953-1965	27
1956	Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. **2020**, 20, 1-11	6
1955	Sex Differences in Mortality Rates and Underlying Conditions for COVID-19 Deaths in England and Wales. **2020**, 95, 2110-2124	22
1954	Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation. **2020**, 144, 110160	42
1953	ANMCO POSITION PAPER: Considerations on in-hospital cardiological consultations and cardiology outpatient clinics during the COVID-19 pandemic. **2020**, 22, G228-G232	0
1952	Preparedness needs research: How fundamental science and international collaboration accelerated the response to COVID-19. **2020**, 16, e1008902	12
1951	Ultrastructure of cell trafficking pathways and coronavirus: how to recognise the wolf amongst the sheep. **2020**, 252, 346-357	6
1950	Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. **2020**, 101, 107730	13
1949	Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. **2020**, 11, 582870	22

1948	Proteomics Insights Into the Molecular Basis of SARS-CoV-2 Infection: What We Can Learn From the Human Olfactory Axis. **2020**, 11, 2101	7
1947	Tissue Proteases and Immune Responses: Influencing Factors of COVID-19 Severity and Mortality. **2020**, 9,	2
1946	The Good, The Bad and The Ugly: A Mathematical Model Investigates the Differing Outcomes Among CoVID-19 Patients. **2020**, 100, 1-9	5
1945	The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues. **2020**, 533, 867-871	40
1944	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. **2020**, 41, 1006-1022	46
1943	Involvement of the nervous system in COVID-19: The bell should toll in the brain. **2020**, 262, 118568	25
1942	Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. **2020**, 263, 118588	16
1941	Drugs and the liver. **2020**, 21, 517-523	2
1940	Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein. **2020**, 4, 100038	13
1939	A systematic review of SARS-CoV-2 vaccine candidates. **2020**, 5, 237	257
1938	Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. **2020**, 11, 5139	68
1937	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. **2020**, 1-24	11
1936	Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). **2020**, 9, 2394-2403	60
1935	Novel coronavirus disease in patients with end-stage kidney disease. **2021**, 25, 544-550	4
1934	Week 2020 Poster Presentations. **2020**, 8, 144-887	3
1933	Nano-sized formazan analogues: Synthesis, structure elucidation, antimicrobial activity and docking study for COVID-19. **2020**, 105, 104354	14
1932	SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. **2020**, 98, 1502-1518	33
1931	Machine Learning Maps Research Needs in COVID-19 Literature. **2020**, 1, 100123	19

1930	New Frontiers for Selective Biosensing with Biomembrane-Based Organic Transistors. **2020**, 14, 12271-12280	14
1929	Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors. **2020**, 3, 1265-1277	95
1928	An Overview of the Progress Made on the Coronavirus Vaccine. **2020**, 185, 03042	
1927	Understanding the SARS-CoV-2 to Manage COVID-19. **2020**, 5, 285-293	
1926	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. **2020**, 117, 26915-26925	49
1925	Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. **2020**, 6,	44
1924	Inhibiting Ebola virus and SARS-CoV-2 entry. **2020**, 370, 167-168	6
1923	Remdesivir against COVID-19 and Other Viral Diseases. **2020**, 34,	97
1922	COVID-19 and obesity: an opportunity for change. **2020**, 11, 2042018820949742	1
1921	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. **2020**, 13, 463-484	5
1920	TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019. **2020**, 11, 575770	2
1919	Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19: Should We Add a Cup of Coffee?. **2020**, 7, 581680	2
1918	COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence. **2020**, 11, 579415	9
1917	Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: A candidate approach against SARS-COV-2. **2020**, 1, 612	6
1916	GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies. **2020**, 132, 110816	7
1915	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. **2020**, 225, 152008	39
1914	Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. **2020**, 41, 1083-1099	87
1913	SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids. **2020**, 27, 951-961.e5	171

1912	DeepH-DTA: Deep Learning for Predicting Drug-Target Interactions: A Case Study of COVID-19 Drug Repurposing. **2020**, 8, 170433-170451	11
1911	Potential Therapeutic Effect of Traditional Chinese Medicine on Coronavirus Disease 2019: A Review. **2020**, 11, 570893	5
1910	Identification of Novel Hypothalamic MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating ACE2 and TMPRSS2 Expression: An In Silico Analysis. **2020**, 10,	20
1909	Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. **2020**, 8, 684-694	48
1908	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. **2020**, 2, 1-23	45
1907	In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. **2020**, 126, 104046	64
1906	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. **2020**, 6, e04900	9
1905	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. **2020**, 41, 1100-1115	345
1904	Vitamin D and survival in COVID-19 patients: A quasi-experimental study. **2020**, 204, 105771	101
1903	Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid. **2020**, 3, 1233-1241	4
1902	A materials-science perspective on tackling COVID-19. **2020**, 1-14	123
1901	High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients. **2020**, 10, 16496	13
1900	Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. **2020**, 319, H1059-H1068	13
1899	Short-Term Follow-Up of Self-Isolated COVID-19 Patients with Smell and Taste Dysfunction in Greece: Two Phenotypes of Recovery. **2020**, 82, 295-303	25
1898	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. **2020**, 8,	3
1897	Peptides: Prospects for Use in the Treatment of COVID-19. **2020**, 25,	13
1896	Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. **2020**, 22, 2248-2257	8
1895	Is vitamin D deficiency a risk factor for COVID-19 in children?. **2020**, 55, 3595-3601	23

1894	Analysis of COVID-19 Pandemic Using Artificial Intelligence. **2020**, 65-73	0
1893	ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19. **2021**, 278, 2637-2640	9
1892	What GI Physicians Need to Know During COVID-19 Pandemic. **2021**, 66, 2865-2875	6
1891	Circulating ACE2: a novel biomarker of cardiovascular risk. **2020**, 396, 937-939	10
1890	Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. **2020**, 19, 919-929	465
1889	[Are renin-angiotensin system inhibitors protective or deleterious in patients with COVID-19?]. **2020**, 2020, 20-24	
1888	The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. **2020**, 182, 114215	28
1887	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. **2020**, 131, 110668	59
1886	Biosurfactants and anti-inflammatory activity: A potential new approach towards COVID-19. **2020**, 17, 72-81	17
1885	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. **2020**, 89, 107372	16
1884	Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. **2020**, 18, 2200-2208	8
1883	Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2. **2020**, 885, 173499	8
1882	Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?. **2020**, 889, 173629	12
1881	SARS-CoV-2 Entry Factors: and Are Expressed in Peri-Implantation Embryos and the Maternal-Fetal Interface. **2020**, 6, 1162-1169	15
1880	Control of systemic inflammation through early nitric oxide supplementation with nitric oxide releasing nanoparticles. **2020**, 161, 15-22	4
1879	Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. **2020**, 165, 18-43	27
1878	Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. **2020**, 53, 487-495	73
1877	Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. **2020**, 20, 193-198	29

1876	Azithromycin: The First Broad-spectrum Therapeutic. **2020**, 100062	1
1875	Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. **2020**, 259, 118275	44
1874	New insights on possible vaccine development against SARS-CoV-2. **2020**, 260, 118421	5
1873	A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations. **2020**, 85, 104507	15
1872	COVID-19, myocardial edema and dexamethasone. **2020**, 145, 110307	6
1871	Immune response in COVID-19: What do we currently know?. **2020**, 148, 104484	11
1870	Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy. **2020**, 5, 153-166	30
1869	Fertility preservation during the COVID-19 pandemic: mitigating the viral contamination risk to reproductive cells in cryostorage. **2020**, 41, 991-997	5
1868	Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. **2020**, 38, 7205-7212	15
1867	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. **2020** , 288, 198141	59
1866	Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. **2020**, 1, 100092	77
1865	Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. **2020**, 19, 4587-4608	26
1864	Imatinib is not a potent anti-SARS-CoV-2 drug. **2020**, 34, 3085-3087	20
1863	Predicting the response of the dental pulp to SARS-CoV2 infection: a transcriptome-wide effect cross-analysis. **2020**, 21, 360-363	13
1862	SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. **2020**, 11, 4938	122
1861	Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. **2020**, 11, 4968	105
1860	Consensus transcriptional regulatory networks of coronavirus-infected human cells. **2020**, 7, 314	14
1859	SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. **2020**, 10, 16471	65

1858	The immuno-oncological challenge of COVID-19.. **2020**, 1, 946-964	52
1857	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. **2020**, 117, 25254-25262	116
1856	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. **2020**, 117, 27141-27147	91
1855	Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. **2020**, 1-24	9
1854	In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2. **2020**, 1-12	3
1853	Making a case for using γδ T cells against SARS-CoV-2. **2020**, 46, 689-702	13
1852	SARS-CoV-2 and the reproductive system: assessment of risk and recommendations for infection control in reproductive departments. **2020**, 66, 343-346	4
1851	Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells. **2020**, 9, 2169-2179	21
1850	Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. **2020**, 9, 2269-2277	18
1849	Insult to Injury-Potential Contribution of Coronavirus Disease-19 to Neuroinflammation and the Development of HIV-Associated Neurocognitive Disorders. **2021**, 37, 601-609	
1848	Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm. **2020**, 13, 903-905	3
1847	An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. **2020**, 13, 1405-1414	21
1846	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. **2020**, 17, 543-558	560
1845	COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients. **2020**, 93, 390-393	40
1844	Viral Coagulopathy in Patients With COVID-19: Treatment and Care. **2020**, 26, 1076029620936776	40
1843	Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis. **2020**, 7, 2054358120938573	72
1842	COVID-19 and andrology: Recommendations of the French-speaking society of andrology (Société d'Andrologie de langue Française SALF). **2020**, 30, 10	11
1841	Oncology-Inspired Treatment Options for COVID-19. **2020**, 61, 1720-1723	11

1840	Oral Microbiome and SARS-CoV-2: Beware of Lung Co-infection. **2020**, 11, 1840	67
1839	Targeting TMPRSS2 in SARS-CoV-2 Infection. **2020**, 95, 1989-1999	48
1838	Hepatic manifestations and impact of COVID-19 on the cirrhotic patient. **2020**, 85, 303-311	1
1837	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. **2020**, 6, 2304-2318	25
1836	Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight. **2020**, 13, 807-811	4
1835	Cholesterol-modifying drugs in COVID-19. **2020**, 1, iqaa001	14
1834	Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. **2021**, 87, 3439-3450	14
1833	Distinct conformational states of SARS-CoV-2 spike protein. **2020**, 369, 1586-1592	552
1832	Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. **2020**, 319, C500-C509	4
1831	COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease. **2020**, 40, 2045-2053	15
1830	Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters. **2020**, 12,	112
1829	Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. **2020**, 76, 1623-1630	51
1828	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. **2020**, 15, 359-386	199
1827	Reply to "MRI Evaluation of the Olfactory Clefts in Patients with SARS-CoV-2 Infection Revealed an Unexpected Mechanism for Olfactory Function Loss". **2020**, 27, 1192	1
1826	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. **2020**, 74, 109721	63
1825	Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. **2020**, 58, 102890	15
1824	Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?. **2020**, 63, 13258-13265	27
1823	SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. **2020**, 11, 3581	158

1822	Immune-mediated approaches against COVID-19. **2020**, 15, 630-645	178
1821	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. **2020**, 26, 1428-1434	223
1820	Are sex discordant outcomes in COVID-19 related to sex hormones?. **2020**, 47, 335-340	26
1819	The molecular virology of coronaviruses. **2020**, 295, 12910-12934	175
1818	Design of engineered surfaces for prospective detection of SARS-CoV-2 using quartz crystal microbalance-based techniques. **2020**, 17, 425-432	27
1817	Covid-19, ACE2 and the kidney. **2020**, 230, e13539	14
1816	Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. **2020**, 50, 798-804	6
1815	The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. **2020**, 296, 205-219	99
1814	Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. **2020**, 94,	89
1813	Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. **2020**, 40, 2033-2044	78
1812	Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. **2020**, 24, 422	378
1811	SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice. **2020**, 33, 593-600	5
1810	The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. **2020**, 16, 2029-2033	70
1809	COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. **2020**, 9,	125
1808	Diabetes and Novel Coronavirus Infection: Implications for Treatment. **2020**, 11, 1915-1924	4
1807	Minireview of progress in the structural study of SARS-CoV-2 proteins. **2020**, 1, 53-61	23
1806	Coagulopathy in COVID-19: Focus on vascular thrombotic events. **2020**, 146, 32-40	31
1805	Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. **2020**, 11, 3518	104

1804	COVID-19 vaccine development and a potential nanomaterial path forward. **2020**, 15, 646-655	302
1803	Impact of COVID-19 Pandemic on Laboratory Utilization. **2020**, 5, 1194-1205	13
1802	Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system. **2020**, 27, 2348-2360	35
1801	COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors. **2020**, 50, 1153-1154	1
1800	Identification of therapeutic target in S2 domain of SARS nCov-2 Spike glycoprotein: Key to design and discover drug candidates for inhibition of viral entry into host cell. **2020**, 19, 2050028	3
1799	New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. **2020**, 18, 216	179
1798	Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. **2020**, 18, 220	46
1797	Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: a review. **2020**, 14, 28	3
1796	Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19. **2020**, 69, 1857-1863	94
1795	Clinical Presentation of COVID-19: Case Series and Review of the Literature. **2020**, 17,	29
1794	Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation. **2020**, 21,	46
1793	Immunoglobulin fragment F(ab') against RBD potently neutralizes SARS-CoV-2 in vitro. **2020**, 182, 104868	34
1792	Tackling COVID-19 pandemic through nanocoatings: Confront and exactitude. **2020**, 3, 100011	40
1791	Particulate matter (PM) enhances RNA virus infection through modulation of innate immune responses. **2020**, 266, 115148	24
1790	Association between COVID-19 and cardiovascular disease. **2020**, 29, 100583	14
1789	Dynamic Regulation of SARS-Cov-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium. **2020**, 5, 871-883	26
1788	Immune response in COVID-19: A review. **2020**, 13, 1619-1629	143
1787	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. **2020**, 257, 118058	9

1786	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. **2020**, 257, 118075	57
1785	SARS-CoV-2 Infections: An ACE in the Hole and Systems Biology Studies-a Research Agenda. **2020**, 95, 1838-1841	3
1784	Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease. **2020**, 144, 110027	6
1783	Natural protection of ocular surface from viral infections - A hypothesis. **2020**, 143, 110082	4
1782	Human Organs-on-Chips for Virology. **2020**, 28, 934-946	50
1781	Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning. **2020**, 19, 4624-4636	102
1780	SARS-CoV-2/COVID-19: a´primer for cardiologists. **2020**, 28, 366-383	9
1779	Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. **2020**, 396, 320-332	446
1778	ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. **2020**, 62, 101123	70
1777	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. **2020**, 53, 100719	79
1776	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. **2020**, 203, 112647	17
1775	COVID-19 and post-mortem microbiological studies. **2020**, 46, 127-138	6
1774	Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches. **2021**, 39, 5638-5656	26
1773	Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. **2020**, 6, 335-337	13
1772	Comment on: COVID-19 and Older Adults: What We Know. **2020**, 68, 2197	2
1771	SARS-CoV-2 (COVID-19) and cystic fibrosis. **2020**, 319, L408-L415	14
1770	SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. **2020**, 21, 182	75
1769	Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. **2020**, 31, 1941-1943	74

1768	SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. **2020**, 69, 1875-1886		35
1767	Pregnancy, Viral Infection, and COVID-19. **2020**, 11, 1672		37
1766	Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes. **2020**, 7, 348		60
1765	Mild and Asymptomatic Covid-19 Infections: Implications for Maternal, Fetal, and Reproductive Health. **2020**, 2,		5
1764	Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions. **2020**, 17, E63		108
1763	A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. **2020**, 17, 1522-1531		52
1762	Diarrhoea and the COVID-19 pandemic. **2020**, 21, 146-150		1
1761	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. *Cell*, **2020**, 182, 843-854.e12	56.2	185
1760	Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. **2020**, 32, 437-446.e5		268
1759	Advances in the possible treatment of COVID-19: A review. **2020**, 883, 173372		38
1758	A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. **2020**, 164, 66-76		25
1757	Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. **2020**, 257, 118096		24
1756	Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2. **2020**, 31, 2021-2045		36
1755	Current and Perspective Diagnostic Techniques for COVID-19. **2020**, 6, 1998-2016		67
1754	The epidemiology and therapeutic options for the COVID-19. **2020**, 3, 71-84		7
1753	The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. **2020**, 129, 864-867		40
1752	Effects of Renin-Angiotensin Inhibition on ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Protease Serine 2) Expression: Insights Into COVID-19. **2020**, 76, e29-e30		25
1751	Musculoskeletal Consequences of COVID-19. **2020**, 102, 1197-1204		115

1750	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. **2020**, 21,	22
1749	Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2. **2020**, 12,	11
1748	A new threat from an old enemy: Re-emergence of coronavirus (Review). **2020**, 45, 1631-1643	137
1747	SARS-CoV-2 as a Factor to Disbalance the Renin-Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production. **2020**, 205, 1198-1206	16
1746	Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. **2020**, 12, 1647-1656	33
1745	Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. **2020**, 180, 1345-1355	604
1744	State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19. **2020**, 2, 100038	10
1743	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. **2020**, 257, 118097	36
1742	Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. **2020**, 257, 118102	141
1741	Obesity and COVID-19: A Virchow's Triad for the 21st Century. **2020**, 120, 1590-1593	10
1740	SARS-CoV2 and pregnancy: An invisible enemy?. **2020**, 84, e13308	20
1739	COVID-19 and post-traumatic stress disorder: A vicious circle involving immunosuppression. **2020**, 26, 876-878	15
1738	Assessment of neurological manifestations in hospitalized patients with COVID-19. **2020**, 27, 2322-2328	19
1737	and expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. **2020**, 8,	26
1736	Gene expression and protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. **2020**, 56,	93
1735	MAIT Cells in COVID-19: Heroes, Villains, or Both?. **2020**, 40, 173-184	3
1734	Pathogenesis and management of myocardial injury in coronavirus disease 2019. **2020**, 22, 1994-2006	19
1733	An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. **2020**, 257, 118105	30

1732	Uso terapéutico de los inhibidores de la enzima convertidora de angiotensina en pacientes con COVID-19: las «dos caras de la moneda». **2020**, 27, 212-222	
1731	Safety perspectives on presently considered drugs for the treatment of COVID-19. **2020**, 177, 4353-4374	9
1730	Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. **2020**, 8,	48
1729	The Anatomic Pathology laboratory adjustments in the era of COVID-19 pandemic: The experience of a laboratory in a Portuguese central hospital. **2020**, 48, 151560	5
1728	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. **2020**, 27, 846-854	275
1727	Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia. **2020**, 56, 68-72	5
1726	Endocytic uptake of SARS-CoV-2: the critical roles of pH, Ca2+, and NAADP. **2020**, 1,	20
1725	Cardiac manifestations in COVID-19 patients-A systematic review. **2020**, 35, 1988-2008	73
1724	Focus on Characteristics of COVID-19 with the Special Reference to the Impact of COVID-19 on the Urogenital System. **2020**, 14, 79-84	3
1723	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea. **2020**, 76, 742-749	26
1722	Endocrine Significance of SARS-CoV-2's Reliance on ACE2. **2020**, 161,	72
1721	Could Ergothioneine Aid in the Treatment of Coronavirus Patients?. **2020**, 9,	29
1720	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. **2020**, 9,	23
1719	Scientific solidarity in the face of the COVID-19 pandemic: researchers, publishers, and medical associations. **2020**, 2, 56-59	4
1718	ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. **2020**, 15, 1682-1690	17
1717	Opportunities for biomaterials to address the challenges of COVID-19. **2020**, 108, 1974-1990	30
1716	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. **2020**, 8, e00623	7
1715	Lessons from dermatology about inflammatory responses in Covid-19. **2020**, 30, e2130	20

1714	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. **2020**, 46, 2265-2283	27
1713	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?. **2020**, 22, 95	11
1712	Obesity and COVID-19: A Fatal Alliance. **2020**, 35, 1-8	19
1711	Vascular Manifestations of COVID-19 - Thromboembolism and Microvascular Dysfunction. **2020**, 7, 598400	27
1710	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). **2020**, 7, 572485	10
1709	Current and Future Direct-Acting Antivirals Against COVID-19. **2020**, 11, 587944	10
1708	Clinical Features and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19. **2020**, 9,	8
1707	Profile of SARS-CoV-2. **2020**, 132, 635-644	2
1706	Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis. **2020**, 11, 1-21	8
1705	Integrative Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular Morphologies. **2020**, 28, 853-866.e576	
1704	New onset diabetes, type 1 diabetes and COVID-19. **2020**, 14, 2211-2217	45
1703	Computational Design of 25-mer Peptide Binders of SARS-CoV-2. **2020**, 124, 10930-10942	23
1702	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. **2020**, 6, 6540-6555	13
1701	COVID-19 during Pregnancy and Postpartum. **2020**, 1-28	8
1700	Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19. **2020**, 2020, 7520746	0
1699	Single-Cell Sequencing of Glioblastoma Reveals Central Nervous System Susceptibility to SARS-CoV-2. **2020**, 10, 566599	3
1698	Coronavirus Disease-19 Infection: Implications on Male Fertility and Reproduction. **2020**, 11, 574761	16
1697	Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity. **2020**, 11, 599729	3

1696	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. **2020**, 21,	2
1695	Clinical Health Care during the COVID-19 Pandemic. **2020**, 9,	
1694	Trace Element Zinc, a Nature's Gift to Fight Unprecedented Global Pandemic COVID-19. **2021**, 199, 3213-3221	7
1693	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. **2020**, 28, 1760-1776	14
1692	Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. **2020**, 117, 29274-29282	13
1691	Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review. **2020**, 5, e085	6
1690	Myocardial Injury at Early Stage and Its Association With the Risk of Death in COVID-19 Patients: A Hospital-Based Retrospective Cohort Study. **2020**, 7, 590688	6
1689	Impact of SARS-CoV-2 on Male Reproductive Health: A Review of the Literature on Male Reproductive Involvement in COVID-19. **2020**, 7, 594364	12
1688	Renal Carcinoma Is Associated With Increased Risk of Coronavirus Infections. **2020**, 7, 579422	8
1687	The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. **2020**, 21,	11
1686	Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2. **2020**, 21,	81
1685	Overcoming nonstructural protein 15-nidoviral uridylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2. **2020**, 2, FDD42	6
1684	Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports. **2020**, 17, 2974-2986	9
1683	SARS-CoV-2 Targets by the pscRNA Profiling of ACE2, TMPRSS2 and Furin Proteases. **2020**, 23, 101744	29
1682	Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran. **2020**, 38, 100792	3
1681	COVID-19 and Body Iron: A Survey on Phenomenological and Genetic Correlations. **2020**, 11, 3996-4000	6
1680	SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. **2020**, 11, 5885	230
1679	Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. **2020**, 36, 264-272	12

1678	Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney. **2020**, 41, 4580-4588	22
1677	Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters. **2020**, 31, 1-11	3
1676	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. **2020**, 11, 5838	122
1675	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. **2020**, 29,	25
1674	Epidemiological and Clinical Characteristics of COVID-19 in Indian Children in the Initial Phase of the Pandemic. **2020**, 57, 914-917	15
1673	Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. **2020**, 10, 19076	14
1672	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. **2020**, 27, 434-441	2
1671	The Secretive Liaison of Particulate Matter and SARS-CoV-2. A Hypothesis and Theory Investigation. **2020**, 11, 579964	6
1670	Bilirubin Levels as Potential Indicators of Disease Severity in Coronavirus Disease Patients: A Retrospective Cohort Study. **2020**, 7, 598870	15
1669	Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. **2020**, 7, 608259	14
1668	The Need for Ocular Protection for Health Care Workers During SARS-CoV-2 Outbreak and a Hypothesis for a Potential Personal Protective Equipment. **2020**, 8, 599757	4
1667	Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model. **2020**, 12,	9
1666	The COVID-19 pandemic and diabetes mellitus. **2020**, 5, e200-e205	3
1665	Clinical and epidemiological features of COVID-19 deaths in Nepal. **2020**, 38, 100797	7
1664	Cells of the adult human heart. **2020**, 588, 466-472	274
1663	Gastrointestinal pathophysiology of SARS-CoV2 - a literature review. **2020**, 10, 523-528	15
1662	Androgen-deprivation therapy and SARS-Cov-2 infection: the potential double-face role of testosterone. **2020**, 11, 2042018820969019	9
1661	Prolonged Neuropsychological Deficits, Central Nervous System Involvement, and Brain Stem Affection After COVID-19-A Case Series. **2020**, 11, 574004	9

1660	Cordycepin: a bioactive metabolite of C and polyadenylation inhibitor with therapeutic potential against COVID-19. **2020**, 1-8	7
1659	COVID-19 and cardiovascular diseases. **2021**, 13, 161-167	1
1658	Three Properties of SARS-CoV-2 That Promote COVID-19. **2020**, 28, 324-326	1
1657	Cardiovascular Manifestations of COVID-19 Infection. **2020**, 9,	49
1656	Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs. **2020**, 11,	22
1655	COVID-19 Infection Detection and Prevention by SARS-CoV-2 Active Antigens: A Synthetic Vaccine Approach. **2020**, 8,	1
1654	Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms. **2021**, 36, 3007-3022	7
1653	Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection. **2021**, 421, 127742	44
1652	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. **2020**, 28, 867-879.e5	168
1651	Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. **2020**, 27, 876-889.e12	85
1650	Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. **2020**, 134, 1123-1127	39
1649	Bimodular effects of D614G mutation on the spike glycoprotein of SARS-CoV-2 enhance protein processing, membrane fusion, and viral infectivity. **2020**, 5, 268	28
1648	Evidence for treatment with estradiol for women with SARS-CoV-2 infection. **2020**, 18, 369	53
1647	Systems Biology Approaches for Therapeutics Development Against COVID-19. **2020**, 10, 560240	5
1646	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. **2020**, 10, 587269	199
1645	Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection. **2020**, 11, 593857	37
1644	Food Ingredients and Active Compounds against the Coronavirus Disease (COVID-19) Pandemic: A Comprehensive Review. **2020**, 9,	92
1643	Impact of COVID-19 on the thyroid gland: an update. **2020**, 1	70

1642	Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. **2020**, 53, 1315-1330.e9	99
1641	SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. **2020**, 11, 6013	450
1640	HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. **2020**, 2, 1391-1400	95
1639	Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. **2020**, 9, 2606-2618	14
1638	The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. **2020**, 9,	14
1637	Pregnancy and Childbirth in the COVID-19 Era-The Course of Disease and Maternal-Fetal Transmission. **2020**, 9,	10
1636	A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. **2020**, 25,	17
1635	Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps. **2020**, 20, 77	5
1634	Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions. **2020**,	51
1633	Possible Correlations between Atherosclerosis, Acute Coronary Syndromes and COVID-19. **2020**, 9,	15
1632	Viral Infection-Induced Gut Dysbiosis, Neuroinflammation, and □Synuclein Aggregation: Updates and Perspectives on COVID-19 and Neurodegenerative Disorders. **2020**, 11, 4012-4016	17
1631	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. **2020**, 117, 32105-32113	96
1630	Multivessel spontaneous coronary artery dissection in a patient after mild COVID-19: A case report.. **2020**, 8, 2050313X20975989	1
1629	Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. **2020**, 21, 1311-1329	16
1628	Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. **2020**, 2,	3
1627	Innate and Adaptive Immunity of Murine Neural Stem Cell-Derived piRNA Exosomes/Microvesicles against Pseudotyped SARS-CoV-2 and HIV-Based Lentivirus. **2020**, 23, 101806	10
1626	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. **2021**, 111, 1066-1085	31
1625	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. **2020**, 7, 2054358120967845	9

1624	SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain. **2020**, 23, 101839	84
1623	Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019. **2020**, 7, ofaa519	3
1622	A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective. **2020**, 13, 140	39
1621	Ocular Involvement in Coronavirus Disease 2019: Up-to-Date Information on Its Manifestation, Testing, Transmission, and Prevention. **2020**, 7, 569126	6
1620	Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. **2020**, 2, e0284	25
1619	The testis in patients with COVID-19: virus reservoir or immunization resource?. **2020**, 9, 1897-1900	7
1618	Impact of Diabetes in Patients Diagnosed With COVID-19. **2020**, 11, 576818	35
1617	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. **2020**, 7, 605236	60
1616	[COVID-19 and the kidneys]. **2020**, 15, 1-5	1
1615	Clinical Characteristics and Outcomes of Severe or Critical COVID-19 Patients Presenting No Respiratory Symptoms or Fever at Onset. **2021**, 7, 1452-1458	3
1614	In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis. **2020**, 10, 20584	29
1613	Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease. **2020**, 11, 570698	6
1612	Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality. **2020**, 11, 561749	22
1611	Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M Protease. **2020**, 25,	23
1610	SARS-CoV-2 and the safety margins of cell-based biological medicinal products. **2020**, 68, 122-124	9
1609	Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. **2020**, 588, 327-330	339
1608	Enhancing host cell infection by SARS-CoV-2. **2020**, 370, 765-766	33
1607	Histological Evidence for the Enteric Nervous System and the Choroid Plexus as Alternative Routes of Neuroinvasion by SARS-CoV2. **2020**, 14, 596439	32

1606	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. **2020**, 28, 880-891.e8	70
1605	Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. **2020**, 146, 111805	18
1604	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. **2020**,	57
1603	Identifying the Zoonotic Origin of SARS-CoV-2 by Modeling the Binding Affinity between the Spike Receptor-Binding Domain and Host ACE2. **2020**, 19, 4844-4856	15
1602	The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses. **2020**, 117, 30687-30698	7
1601	A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. **2020**, 117, 32657-32666	37
1600	A nomogramic model based on clinical and laboratory parameters at admission for predicting the survival of COVID-19 patients. **2020**, 20, 899	6
1599	SARS coronavirus 2: from genome to infectome. **2020**, 21, 318	30
1598	The Perspective on Bio-Nano Interface Technology for Covid-19. **2020**, 2,	7
1597	Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein. **2020**, 25,	3
1596	Convalescent plasma - Is it useful for treating SARS Co-V2 infection?. **2020**, 38, 252-260	4
1595	Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. **2020**, 11, 6122	141
1594	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. **2020**, 588, 682-687	651
1593	Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India. **2020**, 11, 1339-1344	11
1592	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Triggering a Lethal Fight to Keep Control of the Ten-Eleven Translocase (TET)-Associated DNA Demethylation?. **2020**, 9,	1
1591	Full Issue PDF. **2020**, 5, I-CIX	
1590	Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. **2020**, 80, 1104-1122.e9	38
1589	Molecular Dynamics Reveals Complex Compensatory Effects of Ionic Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 Spike/Human Angiotensin-Converting Enzyme 2 Interaction. **2020**, 11, 10446-10453	10

1588	Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit. **2020**, 12, 55649-55658	12
1587	Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies. **2020**, 6, 3174-3189	44
1586	On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies. **2020**, 5, 3655-3677	38
1585	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. **2020**, 11, 6121	36
1584	Time dynamics of COVID-19. **2020**, 10, 21040	18
1583	The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor. **2020**, 8, 6603-6610	13
1582	Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens. **2020**, 9, 2728-2731	18
1581	Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An Analysis. **2020**, 2020, 8893483	14
1580	FDA efficiency for approval process of COVID-19 therapeutics. **2020**, 15, 73	5
1579	Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities. **2020**, 11, 594487	13
1578	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. **2020**, 8,	14
1577	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. **2020**, 25,	8
1576	Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. **2020**, 12,	8
1575	Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. **2020**, 11, 10482-10488	16
1574	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. **2020**, 5, 283	399
1573	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. **2020**, 11, 588409	11
1572	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. **2020**, 7, 606393	17
1571	The "sex gap" in COVID-19 trials: a scoping review. **2020**, 29, 100652	21

1570	Similarity and Specificity of Traditional Chinese Medicine Formulas for Management of Coronavirus Disease 2019 and Rheumatoid Arthritis. **2020**, 5, 30519-30530	3
1569	Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages. **2020**,	35
1568	ACE2 partially dictates the host range and tropism of SARS-CoV-2. **2020**, 18, 4040-4047	14
1567	The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease. **2020**, 15, 2633105520975743	4
1566	Molecular epidemiology of SARS-CoV-2 clusters caused by asymptomatic cases in Anhui Province, China. **2020**, 20, 930	3
1565	Autonomic balance determines the severity of COVID-19 courses. **2020**, 6, 22	15
1564	Efforts at COVID-19 Vaccine Development: Challenges and Successes. **2020**, 8,	47
1563	Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. **2020**, 3, 2000156	9
1562	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. **2020**, 6, 80	86
1561	COVID-19 during Pregnancy and Postpartum. **2020**, 1-37	8
1560	A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. **2020**, 11, 573526	20
1559	Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia. **2020**, 12, 588872	60
1558	Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. **2020**, 21,	8
1557	Antibody-Based Immunotherapeutic Strategies for COVID-19. **2020**, 9,	9
1556	SARS-CoV-2´cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes. **2020**, 24, 100844	0
1555	Attributes of dysgeusia and anosmia of coronavirus disease 2019 (COVID-19) in hospitalized patients. **2020**,	6
1554	Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the Urinary Tract and Their Associations with Clinical Manifestations of COVID-19. **2020**, 13, 3977-3990	16
1553	Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients. **2020**, 7, 580504	10

1552	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. **2020**, 173, 350-361	434
1551	Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection. **2020**, 32, 267-277	4
1550	The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis. **2020**, 888, 173487	7
1549	Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring?. **2020**,	3
1548	Infection of human sweat glands by SARS-CoV-2. **2020**, 6, 84	17
1547	SARS-CoV-2 receptor is co-expressed with elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cells. **2020**, 10, 19522	21
1546	Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection. **2020**, 13, 608-614	7
1545	Long-Term Modeling of SARS-CoV-2 Infection of Cultured Polarized Human Airway Epithelium. **2020**, 11,	38
1544	Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease. **2020**, 5, 21	2
1543	Ultrasound Imaging Findings of Acute Testicular Infection in Patients With Coronavirus Disease 2019: A Single-Center-Based Study in Wuhan, China. **2021**, 40, 1787-1794	19
1542	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. **2020**, 329	4
1541	SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in □Cells. **2020**, 32, 1028-1040.e4	79
1540	Asthma in COVID-19 patients: An extra chain fitting around the neck?. **2020**, 175, 106205	9
1539	Obesity and the increased risk for COVID-19: mechanisms and nutritional management. **2021**, 34, 209-221	4
1538	Human coronaviruses: ophthalmic manifestations. **2020**, 5, e000630	11
1537	Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. **2020**, 39, e106057	100
1536	I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. **2020**, 11, 579220	58
1535	Systematic Analysis of Coronavirus Disease 2019 (COVID-19) Receptor ACE2 in Malignant Tumors: Pan-Cancer Analysis. **2020**, 7, 569414	8

1534	Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of L. (Licorice). **2020**, 11, 558418	4
1533	The Role of Molecular Chaperones in Virus Infection and Implications for Understanding and Treating COVID-19. **2020**, 9,	12
1532	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. **2020**, 12,	20
1531	Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones cl□icas. **2020**, 20, 27-32	0
1530	Peptide and peptide-based inhibitors of SARS-CoV-2 entry. **2020**, 167, 47-65	63
1529	COVID-19 and cardiovascular disease. **2020**, 32, 263-266	1
1528	Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis. **2020**, 50, 1468-1474	5
1527	Defensive Properties of Mucin Glycoproteins during Respiratory Infections-Relevance for SARS-CoV-2. **2020**, 11,	30
1526	Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations. **2020**, 21,	29
1525	Tobacco, but Not Nicotine and Flavor-Less Electronic Cigarettes, Induces ACE2 and Immune Dysregulation. **2020**, 21,	19
1524	Are patients with chronic rhinosinusitis with nasal polyps at a decreased risk of COVID-19 infection?. **2020**, 10, 1182-1185	11
1523	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. **2020**,	42
1522	Patterns of Gustatory Recovery in Patients Affected by the COVID-19 Outbreak. **2020**, 35, 833-837	10
1521	Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. **2020**, 21, 269-272	29
1520	[Neurological damage linked to coronaviruses : SARS-CoV-2 and other human coronaviruses]. **2020**, 36, 775-782	1
1519	Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. **2021**, 39, 7231-7245	29
1518	Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. **2020**, 16, 2992-3000	6
1517	Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution. **2020**, 5,	35

1516	Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?. **2020**, 319, E689-E708	22
1515	Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. **2020**, 17, 231	120
1514	Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. **2020**, 11, 1748	84
1513	Special Issues Encountered When Cancer Patients Confront COVID-19. **2020**, 10, 1380	3
1512	COVID-19: The Immune Responses and Clinical Therapy Candidates. **2020**, 21,	16
1511	COVID-19 and the Kidney: From Epidemiology to Clinical Practice. **2020**, 9,	41
1510	COVID-19 and Obesity: Dangerous Liaisons. **2020**, 9,	64
1509	Postulated Adjuvant Therapeutic Strategies for COVID-19. **2020**, 10,	15
1508	Stem cell therapy for COVID-19: Possibilities and challenges. **2020**, 44, 2182-2191	29
1507	Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. **2020**, 69, 1077-1085	69
1506	Molecular Basis for Pathogenicity of Human Coronaviruses. **2020**, 13, 2385-2405	7
1505	Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2. **2020**, 108, 1176-1184	4
1504	Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor. **2020**, 34, e22594	2
1503	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. **2020**, 1	13
1502	Cardiac Injury Patterns and Inpatient Outcomes Among Patients Admitted With COVID-19. **2020**, 133, 154-161	23
1501	Approaches and Challenges in SARS-CoV-2 Vaccine Development. **2020**, 28, 364-370	64
1500	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. **2020**, 58, 102907	75
1499	COVID-19: A review of the proposed pharmacological treatments. **2020**, 886, 173451	54

1498	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. **2020**, 887, 173467	12
1497	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. **2020**, 98, 1296-1307	91
1496	COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans. **2020**, 84, 104493	48
1495	Why do children seem to be more protected against COVID-19? A hypothesis. **2020**, 143, 110151	3
1494	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. **2020**, 147, 12-17	19
1493	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. **2020**, 27, 942-949	89
1492	[Tracing the origins of SARS-COV-2 in coronavirus phylogenies]. **2020**, 36, 783-796	7
1491	Resolution of coronavirus disease 2019 (COVID-19). **2020**, 18, 1201-1211	38
1490	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. **2020**, 13, 957-975	5
1489	Association between hypertension and pneumonia caused by SARS-CoV-2 in Mexican population. **2020**, 38, 1857-1858	
1488	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. **2020**,	15
1487	Asymptomatic COVID-19 and saliva: Let's ask "Do you feel that saliva in your mouth had reduced in recent times?". **2020**, 74, e13657	1
1486	COVID-19 as a Blood Clotting Disorder Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic Implications for Stroke Thrombectomy. **2020**, 30, 555-561	26
1485	Rheumatology Drugs and COVID-19. **2020**, 20, 1-3	
1484	A gendered magnifying glass on COVID-19. **2020**, 18, 14	14
1483	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. **2020**, 11, 1949	163
1482	SARS-CoV-2 Infection and Lung Cancer: Potential Therapeutic Modalities. **2020**, 12,	7
1481	The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. **2020**, 17,	25

1480	Emerging Therapeutic Modalities against COVID-19. **2020**, 13,	11
1479	An analysis of SARS-CoV-2 cell entry genes identifies the intestine and colorectal cancer as susceptible tissues. **2020**, 107, e452-e454	2
1478	Digital Tomosynthesis and COVID-19: An Improvement in the Assessment of Pulmonary Opacities. **2020**, 56, 761-763	2
1477	Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection. **2020**, 84, 104498	12
1476	Interdiction of Protein Folding for Therapeutic Drug Development in SARS CoV-2. **2020**, 124, 8201-8208	7
1475	Fractional diffusion on the human proteome as an alternative to the multi-organ damage of SARS-CoV-2. **2020**, 30, 081104	10
1474	Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. **2020**, 295, 14040-14052	76
1473	Drugs against SARS-CoV-2: What do we know about their mode of action?. **2020**, 30, 1-10	20
1472	SARS-CoV-2 and the next generations: which impact on reproductive tissues?. **2020**, 37, 2399-2403	23
1471	Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. **2020**, 31, 1-13	18
1470	Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease. **2020**, 9, 56	12
1469	Inhibition of TMPRSS2 by HAI-2 reduces prostate cancer cell invasion and metastasis. **2020**, 39, 5950-5963	12
1468	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. **2020**, 584, 353-363	289
1467	The TLC-Bioautography as a Tool for Rapid Enzyme Inhibitors detection - A Review. **2020**, 1-19	5
1466	Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis. **2020**, 12,	10
1465	COVID-19: a short message to rheumatologists. **2020**, 58, 130-133	3
1464	[The virology of SARS-CoV-2]. **2020**, 61, 789-792	5
1463	OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. **2020**, 884, 173381	9

1462	Mutations Strengthened SARS-CoV-2 Infectivity. **2020**, 432, 5212-5226	221
1461	Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis. **2021**, 39, 6633-6648	17
1460	Promise and challenges in the development of COVID-19 vaccines. **2020**, 16, 2604-2608	22
1459	Vitamin D and COVID-19: Lessons from Spaceflight Analogs. **2020**, 150, 2624-2627	6
1458	Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. **2020**, 6,	514
1457	COvid MEdicaTion (COMET) study: protocol for a cohort study. **2020**, 27, 191-193	3
1456	Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. **2020**, 22, 15	12
1455	Pre-existing traits associated with Covid-19 illness severity. **2020**, 15, e0236240	69
1454	Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. **2020**, 11, 2008	12
1453	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. **2020**, 55, 2556-2564	25
1452	Frequency and outcome of olfactory impairment and sinonasal involvement in hospitalized patients with COVID-19. **2020**, 41, 2331-2338	25
1451	Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. **2020**, 14, 621-637	59
1450	COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. **2020**, 29, 100589	27
1449	Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. **2020**, 100, 107697	32
1448	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. **2020**, 116, 2185-2196	13
1447	Coagulation Status and Venous Thromboembolism Risk in African Americans: A Potential Risk Factor in COVID-19. **2020**, 26, 1076029620943671	17
1446	Preventing SARS-CoV-2 infection by blocking a tissue serine protease. **2020**, 7, 2049936120933076	0
1445	Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using Structure-Based Virtual Screening Approach. **2020**, 11, 1664	109

1444	Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19. **2020**, 7, 196		32
1443	The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. **2020**, 9,		21
1442	The COVID-19 Pandemic: Does Our Early Life Environment, Life Trajectory and Socioeconomic Status Determine Disease Susceptibility and Severity?. **2020**, 21,		14
1441	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. **2020**, 13,		47
1440	COVID-19: Mechanisms of Vaccination and Immunity. **2020**, 8,		43
1439	Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development. **2020**, 8,		11
1438	Sex-related differences in COVID-19 lethality. **2020**, 177, 4375-4385		36
1437	The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System. **2020**, 11, 1582		69
1436	COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella. **2020**, 11, 1714		17
1435	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. **2020**, 11, 1817		104
1434	Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. **2020**, 11, 1841		6
1433	Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. **2020**, 11, 1979		14
1432	Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic. **2020**, 21,		61
1431	Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. **2020**, 72, 1864-1872		108
1430	Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. **2020**, 38, 2209-2217		21
1429	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. **2020**, 180, 114169		19
1428	Detection of COVID-19: A review of the current literature and future perspectives. **2020**, 166, 112455		162
1427	A Thermostable mRNA Vaccine against COVID-19. *Cell*, **2020**, 182, 1271-1283.e16	56.2	255

1426	SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. **2020**, 65, 1075-1082	204
1425	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. **2020**, 38, 1073-1078	528
1424	Controlling the SARS-CoV-2 spike glycoprotein conformation. **2020**, 27, 925-933	200
1423	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.. **2020**, 10, 26895-26916	20
1422	Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane serine protease. **2020**, 295, 12686-12696	10
1421	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. **2020**, 28, 683-699	17
1420	Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. **2020**, 222, 1256-1264	68
1419	Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. **2020**, 177, 4899-4920	35
1418	The role of the renin-angiotensin system in skin physiology and pathophysiology. **2020**, 29, 891-901	9
1417	Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. **2020**, 369, 1501-1505	450
1416	Answer to August 2020 Photo Quiz. **2020**, 58,	
1415	Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures. **2020**, 94,	152
1414	Is there an association between the level of ambient air pollution and COVID-19?. **2020**, 319, L416-L421	24
1413	Geographic components of SARS-CoV-2 expansion: a hypothesis. **2020**, 129, 257-262	8
1412	Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. **2020**, 11, 305	37
1411	SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?. **2020**, 12, e12560	82
1410	Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future. **2020**, 15, 471-482	8
1409	Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. **2020**, 11, 1723	33

1408	BCG Against SARS-CoV-2: Second Youth of an Old Age Vaccine?. **2020**, 11, 1050	7
1407	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. **2020**, 11, 820	12
1406	Advances and challenges in the prevention and treatment of COVID-19. **2020**, 17, 1803-1810	10
1405	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. **2020**, 26, 1306-1314	22
1404	Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. **2020**, 34, 8787-8795	61
1403	Covid-19 Kills More Men Than Women: An Overview of Possible Reasons. **2020**, 7, 131	23
1402	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. **2020**, 21,	27
1401	Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. **2020**, 129, 110500	46
1400	Potential treatment methods targeting 2019-nCoV infection. **2020**, 205, 112687	20
1399	Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages. **2020**, 153, 105495	28
1398	The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2. **2020**, 588, 119689	24
1397	A comparative overview of COVID-19, MERS and SARS: Review article. **2020**, 81, 1-8	45
1396	COVID-19 and SARS-CoV-2. Modeling the present, looking at the future. **2020**, 869, 1-51	90
1395	Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19). **2020**, 148, e164	16
1394	Human neutralizing antibodies elicited by SARS-CoV-2 infection. **2020**, 584, 115-119	982
1393	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. **2020**, 584, 120-124	844
1392	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. **2020**, 10, 28243-28266	25
1391	Drug Discovery Strategies for SARS-CoV-2. **2020**, 375, 127-138	51

1390	Immunometabolic Status of COVID-19 Cancer Patients. **2020**, 100, 1839-1850	9
1389	MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension. **2020**, 142, 1190-1204	31
1388	A Single-Cell Atlas of the Human Healthy Airways. **2020**, 202, 1636-1645	95
1387	The Southwest Monsoon During COVID-19 Pandemic: A Potential Concern. **2020**, 32, 374-375	3
1386	Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. **2020**, 12, 68	228
1385	Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. **2020**, 15, e0235987	47
1384	Interplay between SARS-CoV-2 and the type I interferon response. **2020**, 16, e1008737	244
1383	COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients. **2020**, 15, 1231-1240	18
1382	Renin-Angiotensin-Aldosterone System Blockers Are Not Associated With Coronavirus Disease 2019 (COVID-19) Hospitalization: Study of 1,439 UK Biobank Cases. **2020**, 7, 138	13
1381	COVID-19 and the Kidneys: An Update. **2020**, 7, 423	48
1380	A Message from the Human Placenta: Structural and Immunomodulatory Defense against SARS-CoV-2. **2020**, 9,	28
1379	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. **2020**, 59, 1195-1216	18
1378	Coronavirus Disease of 2019: a Mimicker of Dengue Infection?. **2020**, 2, 1-11	20
1377	Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics. **2020**, 265, 106438	28
1376	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). **2020**, 58, 102887	78
1375	Prior infection with intestinal coronaviruses moderates symptom severity and mortality in patients with COVID-19: A hypothesis and preliminary evidence. **2020**, 143, 110116	1
1374	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. **2020**, 383, 1544-1555	612
1373	Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients. **2020**, 22, 18	42

1372	SARS-CoV-2: characteristics and current advances in research. **2020**, 17, 117	39
1371	Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. **2020**, 11, 1069-1081	21
1370	Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. **2020**, 11, 530	43
1369	Non-invasive Auricular Vagus Nerve Stimulation as a Potential Treatment for Covid19-Originated Acute Respiratory Distress Syndrome. **2020**, 11, 890	20
1368	Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV. **2020**, 30, 1-9	30
1367	COVID-19: A Concern for Cardiovascular Disease Patients. **2020**, 20, 443-447	4
1366	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. **2020**, 28, 745-764	9
1365	SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. **2020**, 1, e218-e225	278
1364	Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. **2020**, 18, 2117-2131	17
1363	SARS-CoV-2 and cancer: Are they really partners in crime?. **2020**, 89, 102068	42
1362	Lactoferrin as potential preventative and adjunct treatment for COVID-19. **2020**, 56, 106118	68
1361	Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19. **2020**, 749, 141364	130
1360	Corneal transplantation in the aftermath of the COVID-19 pandemic: an international perspective. **2020**, 104, 1477-1481	16
1359	COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. **2020**, 26, 1076029620943293	41
1358	Plasmapheresis, Anti-ACE2 and Anti-FcRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19. **2020**, 14, 2607-2611	5
1357	Probing 3CL protease: Rationally designed chemical moieties for COVID-19. **2020**, 81, 911	5
1356	Coronaviruses and the central nervous system. **2020**, 26, 459-473	24
1355	Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases. **2020**, 48, 665-669	35

1354	Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019. **2020**, 190, 2013-2017	34
1353	Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. **2020**, 88, 107351	40
1352	SARS-CoV-2 Vaccine Development: Current Status. **2020**, 95, 2172-2188	61
1351	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. **2020**, 41, 815-829	66
1350	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. **2020**, 43, 1028-1046	65
1349	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. **2020**, 1,	10
1348	Emergent Large Vessel Occlusion Stroke During New York City's COVID-19 Outbreak: Clinical Characteristics and Paraclinical Findings. **2020**, 51, 2656-2663	64
1347	Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. **2020**, 11, 1169	59
1346	Medicinal Plants as Sources of Active Molecules Against COVID-19. **2020**, 11, 1189	73
1345	Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. **2020**, 213, 182-187	32
1344	The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. **2020**, 72, 387-391	16
1343	COVID-19, Virology and Geroscience: A Perspective. **2020**, 24, 685-691	40
1342	COVID-19 and the central nervous system. **2020**, 198, 106116	17
1341	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. **2020**, 59, 102915	78
1340	Vascular occlusion by neutrophil extracellular traps in COVID-19. **2020**, 58, 102925	210
1339	Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. **2020**, 884, 173455	45
1338	Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. **2020**, 7, 551-557	43
1337	Smell and taste disorders in Spanish patients with mild COVID-19. **2020**, 35, 633-638	11

1336	Dynamic Asymmetry Exposes 2019-nCoV Prefusion Spike. **2020**, 11, 7021-7027	22
1335	Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19. **2020**, 6, 2319-2336	27
1334	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. **2020**, 584, 437-442	1167
1333	COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. **2020**, 71, 2191-2194	14
1332	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. **2020**, 116, 2177-2184	184
1331	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. **2020**, 369, 1261-1265	269
1330	Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. **2020**, 20, 561	47
1329	Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?. **2020**, 6, 15	27
1328	Diagnostic and Treatment Strategies for COVID-19. **2020**, 21, 222	17
1327	Prospects for RNAi Therapy of COVID-19. **2020**, 8, 916	40
1326	Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US. **2020**, 9,	106
1325	Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. **2020**, 56,	24
1324	Bioinformatic Analysis of Correlation between Immune Infiltration and COVID-19 in Cancer Patients. **2020**, 16, 2464-2476	9
1323	At High Altitude COVID-19 Is Less Frequent: The Experience of Peru. **2020**, 56, 760-761	13
1322	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. **2020**, 3, 813-834	17
1321	In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. **2021**, 39, 6772-6791	29
1320	Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. **2021**, 39, 6842-6851	21
1319	Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. **2020**, 56,	98

1318	Food and COVID-19: Preventive/Co-therapeutic Strategies Explored by Current Clinical Trials and in Silico Studies. **2020**, 9,	18
1317	Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives. **2020**, 20,	41
1316	Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers. **2020**, 81, 1073	21
1315	Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?. **2020**, 360, 338-341	9
1314	An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. **2020**, 181, 104882	25
1313	Roles of flavonoids against coronavirus infection. **2020**, 328, 109211	124
1312	ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic. **2020**, 23, 101384	8
1311	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. **2020**, 258, 118166	43
1310	SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. **2020**, 33, 2092-2103	117
1309	Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. **2020**, 41, 1141-1149	739
1308	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. **2020**, 27, 950-958	175
1307	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. **2020**, 117, 20803-20813	87
1306	Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. **2020**, 1-16	33
1305	Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. **2021**, 39, 7246-7262	20
1304	Nonsteroidal anti-inflammatory drugs (NSAIDs) consideration by dermatologists during the COVID19 pandemic. **2020**, 1-2	
1303	Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients. **2020**, 9, 1900-1911	36
1302	Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors. **2020**, 85, 104474	11
1301	Future antiviral surfaces: Lessons from COVID-19 pandemic. **2020**, 25, e00203	41

1300	Crosstalk between COVID-19 and prostate cancer. **2020**, 23, 561-563	17
1299	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. **2020**, 26, 2181-2189	27
1298	COVID-19 and liver disease: An update. **2020**, 43, 472-480	12
1297	Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN- and IFN inducer. **2020**, 81, e1-e10	29
1296	The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. **2020**, 257, 118142	11
1295	Kawasaki-like disease in children with COVID-19: A hypothesis. **2020**, 143, 110117	11
1294	Placental barrier against COVID-19. **2020**, 99, 45-49	37
1293	False negative SARS-CoV-2 PCR - A case report and literature review. **2020**, 31, 101140	8
1292	Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19. **2020**, 19, 4567-4575	23
1291	Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes. **2020**, 19, 4609-4623	12
1290	COVID-19: a novel menace for the practice of nephrology and how to manage it with minor devastation?. **2020**, 42, 710-725	7
1289	The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options. **2020**, 39, 1741-1753	23
1288	Association Between Nonsteroidal Antiinflammatory Drug Use and Adverse Clinical Outcomes Among Adults Hospitalized With Coronavirus 2019 in South Korea: A Nationwide Study. **2021**, 73, e4179-e4188	16
1287	Acute Kidney Injury in Patients with the Coronavirus Disease 2019: A Multicenter Study. **2020**, 45, 612-622	18
1286	Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. **2020**, 142, 1117-1119	11
1285	Vascular inflammation and endothelial injury in SARS-CoV-2 infection: The overlooked regulatory cascades implicated by the ACE2 gene cluster. **2020**,	10
1284	Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). **2020**, 83, 725-732	7
1283	Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?. **2020**, 23, 998-1008	7

1282	Potential effects of SARS-CoV-2 infection during pregnancy on fetuses and newborns are worthy of attention. **2020**, 46, 1951-1957		17
1281	Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. **2020**, 7, 444		53
1280	High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. **2020**, 34, 3400-3410		4
1279	Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19. **2020**, 55, 1098-1106		6
1278	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell*, **2020**, 182, 1295-1310.e20	56.2	935
1277	Longitudinal analyses reveal immunological misfiring in severe COVID-19. **2020**, 584, 463-469		901
1276	Single-cell landscape of immunological responses in patients with COVID-19. **2020**, 21, 1107-1118		230
1275	Commentary on: "Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk". **2020**, 98, 382-383		2
1274	Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients. **2020**, 319, L596-L602		5
1273	Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. **2020**, 24, 495		145
1272	Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. **2020**, 9,		14
1271	Association of Nonsteroidal Anti-inflammatory Drug Use and Adverse Outcomes Among Patients Hospitalized With Influenza. **2020**, 3, e2013880		12
1270	Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. **2020**, 3, e2017708		37
1269	Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. **2020**, 16, 1571-1581		61
1268	[Can androgen deprivation therapy play a protective role in SARS-CoV-infections?]. **2020**, 59, 1251-1253		
1267	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. **2020**, 25, 1822-1838		5
1266	Systemic Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server. **2020**, 60, 5735-5745		14
1265	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. **2020**, 584, 450-456		848

1264	Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. **2020**, 34, 13185-13193	75
1263	The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2. **2020**, 83, 712-718	1
1262	Impact of COVID-19 and other viruses on reproductive health. **2020**, 52, e13791	29
1261	Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom. **2020**, 60, 1788-1792	34
1260	Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. **2020**, 35, 288-301	82
1259	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. **2020**, 13, 439-452	26
1258	Immunosuppressive Drugs and COVID-19: A Review. **2020**, 11, 1333	48
1257	SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. **2020**, 21,	35
1256	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. **2020**, 9,	1
1255	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. **2020**, 10,	4
1254	Immune Response and COVID-19: A mirror image of Sepsis. **2020**, 16, 2479-2489	32
1253	Impact of climate and ambient air pollution on the epidemic growth during COVID-19 outbreak in Japan. **2020**, 190, 110042	57
1252	Molecular diagnostic technologies for COVID-19: Limitations and challenges. **2020**, 26, 149-159	137
1251	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. **2020**, 13, 1-26	4
1250	Animal Models to Study Emerging Technologies Against SARS-CoV-2. **2020**, 13, 1-11	6
1249	Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors. **2020**, 13, 1-17	48
1248	Hohes Mortalitätsrisiko bei Diabetespatienten mit COVID-19. **2020**, 14, 16-17	
1247	COVID-19 aus der Sicht der Gastroenterologie. **2020**, 1, 65-67	

1246	Antimalarials as Antivirals for COVID-19: Believe it or Not!. **2020**, 360, 618-630	14
1245	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. **2020**, 57, 236-243	23
1244	Potently neutralizing and protective human antibodies against SARS-CoV-2. **2020**, 584, 443-449	609
1243	COVID-19 and the workplace: Research questions for the aerosol science community. **2020**, 54, 1117-1123	5
1242	Defining heart disease risk for death in COVID-19 infection. **2020**, 113, 876-882	18
1241	Obesity as a contributor to immunopathology in pregnant and non-pregnant adults with COVID-19. **2020**, 84, e13320	8
1240	Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. **2020**, 94,	78
1239	SARS-CoV-2 on the ocular surface: is it truly a novel transmission route?. **2021**, 105, 1190-1195	19
1238	COVID-19 and COPD. **2020**, 56,	124
1237	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge. **2020**, 15, 103	60
1236	SARS-CoV-2 Bound Human Serum Albumin and Systemic Septic Shock. **2020**, 7, 153	19
1235	Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. **2020**, 32, 1609-1612	22
1234	The Pursuit of COVID-19 Biomarkers: Putting the Spotlight on and Regulatory Sequences. **2020**, 7, 582793	8
1233	Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019. **2020**, 11, 577571	24
1232	Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome. **2020**, 21,	20
1231	The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19. **2020**, 10, e200	43
1230	Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells. **2020**, 8, 753-762	8
1229	The burden of type 2 diabetes pre-and during the COVID-19 pandemic - a review. **2020**, 19, 1-9	7

1228	Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. **2020**, 2, 1-10	66
1227	S1-Leitlinie: Neurologische Manifestationen bei COVID-19. **2020**, 3, 495-519	3
1226	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. **2020**, 358, 104240	4
1225	Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. **2020**, 100, 107710	16
1224	Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. **2020**, 52, 760-763	10
1223	Vascular underpinning of COVID-19. **2020**, 10, 200208	16
1222	Why Severe COVID-19 Patients Are at Greater Risk of Developing Depression: A Molecular Perspective. **2020**, 1073858420967892	15
1221	Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era. **2020**, 18, 408	11
1220	Role of Kinins in Hypertension and Heart Failure. **2020**, 13,	9
1219	[The virology of SARS-CoV-2]. **2020**, 17, 1-4	1
1218	Potential neuroinvasive and neurotrophic properties of SARS-CoV-2 in pediatric patients: comparison of SARS-CoV-2 with non-segmented RNA viruses. **2020**, 26, 929-940	1
1217	The Perfect Storm: COVID-19 Health Disparities in US Blacks. **2021**, 8, 1153-1160	27
1216	Electrochemical investigations for COVID-19 detection-A comparison with other viral detection methods. **2021**, 420, 127575	38
1215	Use of protease inhibitors for the prevention of COVID-19. **2020**, 141, 106280	6
1214	COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. **2020**, 5, 256	88
1213	Possible affective cognitive cerebellar syndrome in a young patient with COVID-19 CNS vasculopathy and stroke. **2020**, 13,	7
1212	Cationic drugs and COVID-19. **2020**, 34, 2058738420966078	2
1211	Role of Renin-Angiotensin System in Acute Lung Injury Caused by Viral Infection. **2020**, 13, 3715-3725	19

1210	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. **2020**, 10, 575404	3
1209	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. **2020**, 7, 562142	11
1208	Physical Exercise and the Renin Angiotensin System: Prospects in the COVID-19. **2020**, 11, 561403	4
1207	Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity. **2020**, 9, e1189	23
1206	Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. **2020**, 13, 878-888	22
1205	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. **2020**, 7, 588618	49
1204	Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. **2020**, 9, 100163	91
1203	COVID-19 update: The race to therapeutic development. **2020**, 53, 100733	33
1202	Cardiovascular Manifestations and Mechanisms in Patients with COVID-19. **2020**, 31, 893-904	19
1201	Concanavalin A targeting -linked glycans in spike proteins influence viral interactions. **2020**, 49, 13538-13543	2
1200	Prevention of SARS-CoV-2 cell entry: insight from interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2. **2020**, 1-25	17
1199	SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. **2020**, 217,	325
1198	Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. **2020**, 217,	223
1197	Severe acute respiratory syndrome coronavirus-2 infection and the gut-liver axis. **2020**, 21, 687-695	5
1196	SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. **2020**, 11,	60
1195	Dynamic changes of T-lymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). **2020**, 8, 1145	11
1194	Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. **2020**, 11, 583006	3
1193	Understanding Gender-Bias in Critically Ill Patients With COVID-19. **2020**, 7, 564117	3

1192	Genetic Spectrum and Distinct Evolution Patterns of SARS-CoV-2. **2020**, 11, 593548	23
1191	Thrombosis and COVID-19: The Potential Role of Nutrition. **2020**, 7, 583080	19
1190	Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19). **2020**, 17,	10
1189	COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms. **2020**, 2, 2109-2125	12
1188	Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. **2020**, 31, 100627	17
1187	Applying computer simulations in battling with COVID-19,. **2020**, 21, 100458	8
1186	Cardiorenal Tissues Express SARS-CoV-2 Entry Genes and Basigin (BSG/CD147) Increases With Age in Endothelial Cells. **2020**, 5, 1111-1123	21
1185	Computational Identification of Human Biological Processes and Protein Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using Protein-Protein Interaction Networks. **2020**, 19, 4553-4566	6
1184	The global population of SARS-CoV-2 is composed of six major subtypes. **2020**, 10, 18289	29
1183	Catecholamine physiology and its implications in patients with COVID-19. **2020**, 8, 978-986	19
1182	ACE2 coding variants in different populations and their potential impact on SARS-CoV-2 binding affinity. **2020**, 24, 100798	18
1181	Probing infectious disease by single-cell RNA sequencing: Progresses and perspectives. **2020**, 18, 2962-2971	8
1180	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. **2020**, 88, 106980	20
1179	SARS-CoV-2 Infection Boosts Antiviral Effector in COVID-19 Patients. **2020**, 23, 101585	32
1178	The nervous system-A new territory being explored of SARS-CoV-2. **2020**, 82, 87-92	3
1177	A graph-based approach identifies dynamic H-bond communication networks in spike protein S of SARS-CoV-2. **2020**, 212, 107617	19
1176	Electrochemical SARS-CoV-2 Sensing at Point-of-Care and Artificial Intelligence for Intelligent COVID-19 Management. **2020**, 3, 7306-7325	80
1175	Targeting Crucial Host Factors of SARS-CoV-2. **2020**, 6, 2844-2865	13

1174	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. **2020**, 3, 1165-1175	42
1173	Genetically modified mouse models to help fight COVID-19. **2020**, 15, 3777-3787	15
1172	RAAS Inhibitors and Risk of Covid-19. **2020**, 383, 1990-1991	10
1171	High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein. **2020**, 1-14	16
1170	COVID-19-Lessons Learned and Questions Remaining. **2021**, 72, 2225-2240	34
1169	Acute Pancreatitis During COVID-19 Pneumonia. **2020**, 49, e106-e108	5
1168	Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. **2020**, 63, 2-9	11
1167	A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. **2020**, 18, 390	21
1166	Patient Satisfaction and Associated Factors During COVID-19 Pandemic in North Shoa Health Care Facilities. **2020**, 14, 1923-1934	16
1165	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19). **2020**, 16, 933-946	4
1164	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. **2020**, 11, 562264	5
1163	Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. **2020**, 38, 100786	30
1162	ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients. **2020**, 29, 963689720968749	14
1161	Lung Secretoglobin Scgb1a1 Influences Alveolar Macrophage-Mediated Inflammation and Immunity. **2020**, 11, 584310	9
1160	High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States. **2020**, 33, 108352	23
1159	Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA. **2020**, 80, 1055-1066.e6	65
1158	Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads. **2020**, 100, 69-74	50
1157	Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. **2020**, 31, 918-927	31

1156	ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. **2020**, 11, 5453		100
1155	Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. **2020**, 11, 5413		105
1154	Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. **2020**, 120, 1629-1641		25
1153	analysis of the interactions of certain flavonoids with the receptor-binding domain of 2019 novel coronavirus and cellular proteases and their pharmacokinetic properties. **2020**, 1-15		14
1152	Inhibition of Coronavirus Entry and by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. **2020**, 11,		33
1151	The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia. **2020**, 6, 20		3
1150	Triglyceride to High-Density Lipoprotein Cholesterol Ratio is an Important Determinant of Cardiovascular Risk and Poor Prognosis in Coronavirus Disease-19: A Retrospective Case Series Study. **2020**, 13, 3925-3936		15
1149	Host Genetic Variants Potentially Associated With SARS-CoV-2: A Multi-Population Analysis. **2020**, 11, 578523		11
1148	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. **2020**, 11, 576622		137
1147	Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. **2020**, 11, 554172		4
1146	COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance. **2020**, 9,		61
1145	Aprotinin Inhibits SARS-CoV-2 Replication. **2020**, 9,		42
1144	Covid-19: Fat, Obesity, Inflammation, Ethnicity, and Sex Differences. **2020**, 9,		10
1143	Kakkonto, shosaikoto, Platycodon grandiflorum root, and gypsum (a Japanese original combination drug known as saikatsugekito): Pharmacological review of its activity against viral infections and respiratory inflammatory conditions and a discussion of its applications to COVID-19. **2020**, 7, 115-127		10
1142	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. **2020**, 113, 797-810		1
1141	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell*, **2020**, 183, 1367-1382.e17	56.2	217
1140	Smell and taste disorders in Spanish patients with mild COVID-19. **2020**, 35, 633-638		0
1139	Coronavirus disease 2019 and the pancreas. **2020**, 20, 1567-1575		28

1138	Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance. **2020**, 5, 3328-3345	22
1137	Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges. **2020**, 8,	5
1136	CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. **2020**, 11, 599587	13
1135	Mucin-Inspired, High Molecular Weight Virus Binding Inhibitors Show Biphasic Binding Behavior to Influenza A Viruses. **2020**, 16, e2004635	9
1134	identification of drug candidates against COVID-19. **2020**, 21, 100461	5
1133	Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. **2020**, 76, 2334-2348	78
1132	Role of testosterone in COVID-19 patients - A double-edged sword?. **2020**, 144, 110287	14
1131	Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation. **2020**, 6, 71	14
1130	Comparative ACE2 variation and primate COVID-19 risk. **2020**, 3, 641	83
1129	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. **2020**, 10, 200160	116
1128	Animal models for SARS-CoV-2 research: A comprehensive literature review. **2021**, 68, 1868-1885	28
1127	Alteration in angiotensin-converting enzyme 2 by PM during the development of emphysema in rats. **2020**, 6,	7
1126	Targeting Lipid Rafts-A Potential Therapy for COVID-19. **2020**, 11, 574508	19
1125	Expression Pattern of the SARS-CoV-2 Entry Genes and in the Respiratory Tract. **2020**, 12,	12
1124	A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases. **2020**, 136, 155228	4
1123	The role of androgens in COVID-19. **2020**, 14, 2003-2006	24
1122	Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects. **2020**, 165, 1626-1633	10
1121	Novel Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. **2020**, 28, 1243-1252	3

1120	The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review. **2020**, 289, 198163	28
1119	Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. **2020**, 11, 5337	23
1118	Deep mutagenesis in the study of COVID-19: a technical overview for the proteomics community. **2020**, 17, 633-638	5
1117	Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. **2020**, 217,	41
1116	An ace model for SARS-CoV-2 infection. **2020**, 217,	2
1115	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. **2020**, 11,	34
1114	Surfactant replacement might help recovery of low-compliance lung in severe COVID-19 pneumonia. **2020**, 14, 1753466620951043	16
1113	Risk factors and outcome of COVID-19 in patients with hematological malignancies. **2020**, 9, 21	57
1112	SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. **2020**, 9,	30
1111	Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms. **2020**, 57, 5263-5275	37
1110	COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?. **2020**, 196, 143-151	41
1109	Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. **2020**, 35, 1353-1361	52
1108	The clinical characteristics of coronavirus-associated nephropathy. **2020**, 35, 1279-1281	6
1107	Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in COVID-19 patients. **2020**, 98, 2376-2383	27
1106	Prognostic Value of Elevated Cardiac Troponin I in Hospitalized Covid-19 Patients. **2020**, 135, 150-153	19
1105	The Resilient Child: Sex-Steroid Hormones and COVID-19 Incidence in Pediatric Patients. **2020**, 4, bvaa106	9
1104	COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells. **2020**, 11,	48
1103	A Decision Aide for the Risk Stratification of GU Cancer Patients at Risk of SARS-CoV-2 Infection, COVID-19 Related Hospitalization, Intubation, and Mortality. **2020**, 9,	4

1102	Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?. **2020**, 10,	3
1101	Host genetic factors and susceptibility to SARS-CoV-2 infection. **2020**, 32, e23497	3
1100	Snatching the Crown from SARS-CoV-2. **2020**, 28, 360-363	4
1099	Spontaneous subcutaneous emphysema and pneumomediastinum in non-intubated patients with COVID-19. **2020**, 67, 207-213	25
1098	Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. **2020**, 2, 1021-1024	86
1097	Soft matter science and the COVID-19 pandemic. **2020**, 16, 8310-8324	33
1096	Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2). **2020**, 16, 3001-3010	5
1095	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. **2020**, 16, 2980-2991	16
1094	COVID-19 in Hospitalized Adults With HIV. **2020**, 7, ofaa327	21
1093	Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study. **2020**, 13, 1096-1102	21
1092	Gene of the month: (transmembrane serine protease 2). **2020**, 73, 773-776	36
1091	Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis. **2020**, 76, 1563-1571	19
1090	Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders?. **2020**, 12, 1759091420954960	32
1089	Lipidomics Issues on Human Positive ssRNA Virus Infection: An Update. **2020**, 10,	4
1088	Molecular mechanisms involved in the positive effects of physical activity on coping with COVID-19. **2020**, 120, 2569-2582	22
1087	An Indian study: impact of COVID-19 on clinical decision-making and consensus in cardiac surgery practice across the country. **2020**, 36, 1-13	2
1086	Locked-In with COVID-19. **2020**, 79, 80-83	8
1085	Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an assisted drug-repurposing study. **2020**, 1-11	18

1084	Ocular manifestations in SARS-CoV-2 positive patients: a systematic review. **2020**, 15, 367-375	1
1083	Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing. **2020**, 29, 1365-1369	7
1082	A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell Culture. **2020**, 5,	20
1081	Elevated FiO increases SARS-CoV-2 co-receptor expression in respiratory tract epithelium. **2020**, 319, L670-L674	7
1080	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. **2020**, 19, 40	62
1079	Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations. **2020**, 11, 1039	35
1078	SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. **2020**, 52, 801-808	40
1077	Immunological considerations for COVID-19 vaccine strategies. **2020**, 20, 615-632	480
1076	Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients. **2020**, 40, 321-330	15
1075	COVID-19-related disease severity in pregnancy. **2020**, 84, e13339	9
1074	SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. **2020**, 13, 120	265
1073	Genetic Association of rs2285666 Polymorphism With COVID-19 Spatial Distribution in India. **2020**, 11, 564741	36
1072	Computational and Transcriptome Analyses Revealed Preferential Induction of Chemotaxis and Lipid Synthesis by SARS-CoV-2. **2020**, 9,	7
1071	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. **2020**, 25,	46
1070	Potential of Ocular Transmission of SARS-CoV-2: A Review. **2020**, 4,	19
1069	Drug repurposing approach to fight COVID-19. **2020**, 72, 1479-1508	165
1068	Acute kidney injury during the COVID-19 outbreak. **2020**, 35, 1635-1641	1
1067	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. **2020**, 13,	26

1066	Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. **2020**, 108, 1185-1194	39
1065	Using primary literature on SARS-CoV-2 to promote student learning about evolution. **2020**, 10, 12418	1
1064	COVID-19 and Extracellular Vesicles: An Intriguing Interplay. **2020**, 45, 661-670	28
1063	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. **2020**, 18, 359	15
1062	(SARS-CoV-2) Exhibits High Predicted Binding Affinity to ACE2 from Lagomorphs (Rabbits and Pikas). **2020**, 10,	10
1061	A Call for Action to Safely Deliver Oral Health Care during and Post COVID-19 Pandemic. **2020**, 17,	3
1060	Kinins and Their Receptors in Infectious Diseases. **2020**, 13,	12
1059	The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. **2020**, 6, 1-10	9
1058	Carotane sesquiterpenes from : analysis as SARS-CoV-2 binding inhibitors.. **2020**, 10, 34541-34548	4
1057	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. **2020**, 116, 2207-2215	101
1056	Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review. **2020**, 18, 358	51
1055	Stroke care in Italy at the time of the COVID-19 pandemic: a lesson to learn. **2021**, 268, 2307-2313	5
1054	Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. **2020**, 15, 1485-1499	44
1053	Cytokine Hemoadsorption in the Management of a Pregnant Woman with COVID-19 Pneumonia: Case Report. **2020**, 2, 1-5	1
1052	Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. **2020**, 6, 1722-1734	340
1051	Does severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cause orchitis in patients with coronavirus disease 2019 (COVID-19)?. **2020**, 18, 129-133	5
1050	COVID-19: benefits and risks of passive immunotherapeutics. **2020**, 16, 2963-2972	5
1049	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. **2020**, 370, 950-957	314

1048	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends". **2020**, 11, 2059		11
1047	Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. **2020**, 11, 2159		6
1046	Neurological Damage by Coronaviruses: A Catastrophe in the Queue!. **2020**, 11, 565521		19
1045	Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses. **2020**, 12,		5
1044	SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. **2020**, 34, 14103-14119		20
1043	Systematic Review and Meta-analysis of Smell and Taste Disorders in COVID-19. **2020**, 4, 2473974X20957975		40
1042	Molecular Architecture of the SARS-CoV-2 Virus. *Cell*, **2020**, 183, 730-738.e13	56.2	385
1041	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. *Cell*, **2020**, 183, 1013-1023.e13	56.2	145
1040	Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis. **2020**, 144, 110254		17
1039	SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. **2020**, 27, 962-973.e7		136
1038	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. **2020**, 27, 937-950.e9		151
1037	COVID19: an announced pandemic. **2020**, 11, 799		23
1036	Vertical transmission of SARS-CoV-2 infection in early pregnancy: what is the evidence?. **2020**, 1-2		1
1035	Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates. **2020**, 34, 14160-14165		23
1034	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. **2020**, 39, 200		15
1033	Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19. **2020**, 27, 561-568		12
1032	Lung Barrier Function in COVID-19?. **2020**, 2, 1-3		4
1031	Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients. **2020**, 100, 449-454		31

1030	STAT3 isoforms differentially affect ACE2 expression: A potential target for COVID-19 therapy. **2020**, 24, 12864-12868	5
1029	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. **2020**, 25, 1108-1122	20
1028	SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?. **2020**, 21,	11
1027	Trendbericht Biochemie: Strukturbiologie von Sars-Cov-2 mit NMR-Spektroskopie. **2020**, 68, 55-58	
1026	The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19. **2020**, 28, 813-814	1
1025	Artificial intelligence in COVID-19 drug repurposing. **2020**, 2, e667-e676	188
1024	Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. **2020**, 136, 149-155	96
1023	Evaluation of organ function in patients with severe COVID-19 infections. **2020**, 155, 191-196	4
1022	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. **2020**, 3, 790-800	14
1021	SARS-CoV-2 Vaccine Development: An Overview and Perspectives. **2020**, 3, 844-858	20
1020	Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2. **2020**, 5, 170	9
1019	Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors. **2020**, 153, 115101	18
1018	SARS-CoV-2 Targeting the Retina: Host-virus Interaction and Possible Mechanisms of Viral Tropism. **2020**, 28, 1301-1304	10
1017	Sex differences in severity and mortality from COVID-19: are males more vulnerable?. **2020**, 11, 53	109
1016	The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives. **2020**, 33, 21-27	25
1015	Prevalence of Kidney Injury and Associations with Critical Illness and Death in Patients with COVID-19. **2020**, 15, 1549-1556	13
1014	POTENTIAL THERAPEUTIC AVENUES FOR COVID-19 THERAPY. **2020**, 11-14	1
1013	Single Cell RNA-seq Data Analysis Reveals the Potential Risk of SARS-CoV-2 Infection Among Different Respiratory System Conditions. **2020**, 11, 942	4

1012	Neurological Implications of Non-critically Ill Patients With Coronavirus Disease 2019 in a Fangcang Shelter Hospital in Wuhan, China. **2020**, 11, 895	4
1011	The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease. **2020**, 11, 1044	18
1010	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. **2020**, 21,	32
1009	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. **2020**, 9,	7
1008	COVID-19-Induced Thrombosis in Patients without Gastrointestinal Symptoms and Elevated Fecal Calprotectin: Hypothesis Regarding Mechanism of Intestinal Damage Associated with COVID-19. **2020**, 5,	17
1007	SeXX and COVID-19: tussle between the two. **2020**, 90,	11
1006	Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection. **2020**, 101, 42-45	13
1005	Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. **2020**, 370, 725-730	182
1004	MS, pregnancy and COVID-19. **2020**, 26, 1137-1146	3
1003	Anal swab as a potentially optimal specimen for SARS-CoV-2 detection to evaluate hospital discharge of COVID-19 patients. **2020**, 15, 1101-1107	10
1002	Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs. **2020**, 8, 497	10
1001	Risk Factors, Presentation, and Course of Coronavirus Disease 2019 in a Large, Academic Long-Term Care Facility. **2020**, 21, 1378-1383.e1	53
1000	Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data. **2020**, 112, 154345	36
999	Lifting the mask on neurological manifestations of COVID-19. **2020**, 16, 636-644	190
998	Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets.. **2020**, 10, 31385-31399	18
997	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. **2020**, 78,	10
996	COVID-19 and the Cardiovascular System. **2020**, 43, 381-389	6
995	Electrocautery, Diathermy, and Surgical Energy Devices: Are Surgical Teams at Risk During the COVID-19 Pandemic?. **2020**, 272, e257-e262	22

994	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. **2020**, 7, 143	23
993	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. **2020**, 8, 937	10
992	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. **2020**, 12,	49
991	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). **2020**, 63, 13205-13227	18
990	Central Nervous System Targets and Routes for SARS-CoV-2: Current Views and New Hypotheses. **2020**, 11, 2793-2803	27
989	COVID-19 and renin-angiotensin system modulators: what do we know so far?. **2020**, 18, 743-748	3
988	Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. **2020**, 21, e13128	427
987	Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. **2020**, 16, e1008820	9
986	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). **2020**, 43, 1055-1063	30
985	The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review. **2020**, 6, 215-231	7
984	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. **2020**, 2, 1-11	15
983	A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic. **2020**, 100, 216-223	33
982	Protein Surface Printer for Exploring Protein Domains. **2020**, 60, 5255-5264	1
981	Nanoparticle-Based Strategies to Combat COVID-19. **2020**, 3, 8557-8580	90
980	Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19. **2020**, 16, 645-652	33
979	The diagnostic methods in the COVID-19 pandemic, today and in the future. **2020**, 20, 985-993	20
978	Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns. **2020**, 19, 691-698	13
977	Epithelial cell-specific loss of function of causes a spontaneous COPD-like phenotype and up-regulates expression in mice. **2020**, 6, eabb7238	8

976	SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig. **2020**, 94,	48
975	Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. **2020**, 48, 300060520949077	14
974	Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. **2020**, 192, E1156-E1161	19
973	Can Drinking Microfiltered Raw Immune Milk From Cows Immunized Against SARS-CoV-2 Provide Short-Term Protection Against COVID-19?. **2020**, 11, 1888	9
972	ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. **2020**, 9,	25
971	Thrombosis in COVID-19. **2020**, 95, 1578-1589	92
970	Elevated carcinoembryonic antigen in patients with COVID-19 pneumonia. **2020**, 146, 3385-3388	5
969	Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis. **2020**, 14, 12234-12247	45
968	Obesity: A critical risk factor in the COVID-19 pandemic. **2020**, 10, e12403	81
967	MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses. **2020**, 370, 241-247	33
966	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. **2020**, 76, 1339-1349	86
965	Azithromycin Downregulates Gene Expression of IL-1 and Pathways Involving TMPRSS2 and TMPRSS11D Required by SARS-CoV-2. **2020**, 63, 707-709	11
964	Management of a Parkinson's disease patient with severe COVID-19 pneumonia. **2020**, 11, 20406223209494236	
963	Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease in Different Populations. **2020**, 11, 872	22
962	Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?. **2020**, 11, 2014	25
961	The Immune Response and Immunopathology of COVID-19. **2020**, 11, 2037	61
960	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. **2020**, 11, 1818	50
959	CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2. **2020**, 11, 1858	13

958	Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?. **2020**, 9,	2
957	In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection. **2020**, 25,	32
956	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. **2020**, 43, 1297-1308	35
955	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. **2020**, 11, 4303	94
954	Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. **2020**, 26, 1676-1682	20
953	From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. **2020**, 21, 224	223
952	Is Nanotechnology Helping in the Fight Against COVID-19?. **2020**, 2,	19
951	Implication of Aging Related Chronic Neuroinflammation on COVID-19 Pandemic. **2020**, 10,	16
950	Monocyte activation in systemic Covid-19 infection: Assay and rationale. **2020**, 59, 102964	44
949	Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection. **2020**, 9,	6
948	Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). **2020**, 46, 3-16	178
947	Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. **2020**, 42, e2000094	39
946	Various Facets of Pathogenic Lipids in Infectious Diseases: Exploring Virulent Lipid-Host Interactome and Their Druggability. **2020**, 253, 399-423	9
945	Entry Inhibitors: Efficient Means to Block Viral Infection. **2020**, 253, 425-444	17
944	Central neurological complications and potential neuropathogenesis of COVID-19. **2020**, 15, 1605-1608	3
943	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. **2020**, 6, 1-9	37
942	COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?. **2020**, 35, 700-701	1
941	Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19. **2020**, 11,	20

940	The Natural-Mineral-Based Novel Nanomaterial IFMC Increases Intravascular Nitric Oxide without Its Intake: Implications for COVID-19 and beyond. **2020**, 10,	1
939	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. **2020**, 120, 1597-1628	73
938	Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. **2020**, 33, 1102-1111	27
937	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. **2020**, 58,	110
936	Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. **2020**, 11,	81
935	Silent hypoxia: a frequently overlooked clinical entity in patients with COVID-19. **2020**, 13,	18
934	Vimentin as a target for the treatment of COVID-19. **2020**, 7,	13
933	Age-Dependent Assessment of Genes Involved in Cellular Senescence, Telomere, and Mitochondrial Pathways in Human Lung Tissue of Smokers, COPD, and IPF: Associations With SARS-CoV-2 COVID-19 ACE2-TMPRSS2-Furin-DPP4 Axis. **2020**, 11, 584637	26
932	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. **2020**, 12,	32
931	Antibody response to SARS-Co-V-2, diagnostic and therapeutic implications. **2020**, 4, 1731	4
930	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. **2020**, 22, 90	22
929	Geographical Overlap Between Alpha-1 Antitrypsin Deficiency and COVID-19 Infection in Italy: Casual or Causal?. **2020**, 56, 609-610	23
928	An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. **2020**, 3, 997-1007	58
927	Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. **2020**, 295, 15174-15182	19
926	Potential protease inhibitors and their combinations to block SARS-CoV-2. **2020**, 1-15	7
925	Naltrexone a potential therapeutic candidate for COVID-19. **2020**, 1-8	8
924	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. **2020**, 16, 2921-2931	37
923	RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. **2020**, 72, 862-898	69

922	Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis. **2020**, 14, 30	40
921	COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. **2020**, 77, 459-504	39
920	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases.. **2020**, 2, 571030	12
919	Smoking and COVID-19: Adding Fuel to the Flame. **2020**, 21,	31
918	Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction. **2020**, 25,	6
917	Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?. **2020**, 9,	0
916	Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. **2020**, 12,	28
915	SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics. **2020**, 72, 2331-2354	16
914	ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. **2020**, 28, 1477-1480	8
913	Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods. **2020**, 10, 422	18
912	Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. **2020**, 585, 588-590	243
911	Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation. **2020**, 383, 1168-1180	6
910	Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing Risk Factor for Severe COVID-19. **2020**, 5,	3
909	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. **2020** , 26, 1076029620954911	7
908	Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?. **2020**, 10,	23
907	ACE polymorphisms and COVID-19-related mortality in Europe. **2020**, 98, 1505-1509	21
906	Neuromuscular presentations in patients with COVID-19. **2020**, 41, 3039-3056	98
905	Obesity is a potential risk factor contributing to clinical manifestations of COVID-19. **2020**, 44, 2479-2485	26

904	Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design. **2020**, 7, 309	15
903	The Intestinal Perspective of COVID-19: NOS2 and AOC1 Genes as Epidemiological Factors, and a Homeopathic Approach to their Functional Improvement. **2020**, 33, 196-221	1
902	A Multicentered Study on Epidemiologic and Clinical Characteristics of 37 Neonates With Community-acquired COVID-19. **2020**, 39, e297-e302	18
901	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. **2020**, 54, 416-437	22
900	Pathophysiology and treatment strategies for COVID-19. **2020**, 18, 353	28
899	Expression of ACE2 and a viral virulence-regulating factor CCN family member 1 in human iPSC-derived neural cells: implications for COVID-19-related CNS disorders. **2020**, 40, 32	9
898	The New Coronavirus COVID-19 Infection. **2020**, 35, 53-60	3
897	Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. **2020**, 8, 559841	23
896	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. **2020**, 8, 572885	32
895	Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients at Risk?. **2020**, 13,	6
894	Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus. **2020**, 12,	26
893	Ferritin Nanocage-Based Methyltransferase SETD6 for COVID-19 Therapy. **2020**, 30, 2006110	3
892	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. **2020**, 72, 2313-2330	7
891	A Concise Review of Baseline Facts of SARS-CoV-2 for Interdisciplinary Research. **2020**, 5, 10897-10923	4
890	Ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte predict all-cause mortality in inpatients with coronavirus disease 2019 (COVID-19): a retrospective cohort study in a single medical centre. **2020**, 148, e211	23
889	SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. **2020**, 11, 4698	81
888	Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study. **2020**, 1-22	23
887	Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia. **2020**, 1-11	35

886	COVID-19 and seizures: Is there a link?. **2020**, 61, 1840-1853	36
885	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. **2020**, 22, 1780-1788	13
884	Effects of Asthma and Human Rhinovirus A16 on the Expression of SARS-CoV-2 Entry Factors in Human Airway Epithelium. **2020**, 63, 859-863	11
883	COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. **2020**, 69, 2549-2565	40
882	Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. **2020**, 10, 1448	23
881	A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19. **2020**, 59, 102936	10
880	Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract - A review of patent literature. **2020**, 30, 807-824	7
879	Hypertension and Age-Related Cognitive Impairment: Common Risk Factors and a Role for Precision Aging. **2020**, 22, 80	11
878	Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. **2020**, 9, 2105-2113	62
877	In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. **2020**, 18, e3000849	129
876	Optimal delivery management for the prevention of early neonatal SARS-CoV-2 infection. **2020**,	78
875	Managing rheumatic diseases during COVID-19. **2020**, 39, 3245-3254	10
874	Propofol and SARS-CoV-2 infection. **2020**, 125, e475-e476	4
873	From ACE2 to COVID-19: A multiorgan endothelial disease. **2020**, 100, 425-430	6
872	MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. **2020**, 148, 46-49	47
871	Praktische Empfehlungen der Deutschen Diabetes Gesellschaft zum Diabetesmanagement bei Patientinnen und Patienten mit einer COVID-19-Erkrankung. **2020**, 15, 241-246	2
870	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. **2020**, 66, 1538-1547	70
869	Heterogeneous groups of alveolar type II cells in lung homeostasis and repair. **2020**, 319, C991-C996	7

868	Genomic Cues From Beta-Coronaviruses and Mammalian Hosts Sheds Light on Probable Origins and Infectivity of SARS-CoV-2 Causing COVID-19. **2020**, 11, 902	3
867	Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. **2020**, 21,	12
866	High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma. **2020**, 25,	4
865	[COVID-19 infection-update]. **2020**, 25, 1-8	
864	Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers. **2021**, 8, 973-980	15
863	Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. **2020**, 100, 112-116	115
862	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. **2020**, 5, 1185-1191	329
861	[COVID-19: Questions and answers from infectiology]. **2020**, 145, 1051-1056	1
860	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. **2020**, 15, e0238089	41
859	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. **2020**, 15, 2411-2427	13
858	Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors Driving Pathogenesis of SARS-CoV-2. **2020**, 8, 783	49
857	Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. **2020**, 9,	16
856	Covid-19: Perspectives on Innate Immune Evasion. **2020**, 11, 580641	64
855	Racial/Ethnic Variation in Nasal Gene Expression of Transmembrane Serine Protease 2 (TMPRSS2). **2020**, 324, 1567-1568	30
854	Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics*. **2020**, 26, 15140-15144	26
853	[Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers]. **2020**, 74, 611-614	
852	COVID-19 in the Healthy Patient Population: Demographic and Clinical Phenotypic Characterization and Predictors of In-Hospital Outcomes. **2020**, 40, 2764-2775	12
851	Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. **2020**, 70, 480-504	16

850	Dendritic Cells and SARS-CoV-2 Infection: Still an Unclarified Connection. **2020**, 9,	29
849	The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). **2020**, 21,	16
848	Scoping review: hotspots for COVID-19 urological research: what is being published and from where?. **2021**, 39, 3151-3160	1
847	Virological Characterization of the First 2 COVID-19 Patients Diagnosed in Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody Response Kinetics. **2020**, 7, ofaa403	9
846	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. **2020**, 83, 812-816	10
845	COVID-19 Pandemic: A Case for Phytomedicines. **2020**, 15, 1934578X20945086	14
844	The protein expression profile of ACE2 in human tissues. **2020**, 16, e9610	405
843	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. **2020**, 180, 1356-1362	152
842	Obesity, noncommunicable diseases, and COVID-19: A perfect storm. **2020**, 32, e23484	9
841	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). **2020**, 98, 1369-1383	19
840	[ACE2 - the hijacked all-rounder]. **2020**, 15, 1-4	0
839	The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). **2020**, 35, 1-12	9
838	An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. **2020**, 10, 13866	61
837	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. **2020**, 2, e0178	25
836	The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. **2020**, 25, 522-544	9
835	Cyclosporine: an old weapon in the fight against coronaviruses. **2020**, 56,	11
834	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. **2020**, 10, 1555	4
833	COVID-19 Therapeutic Options Under Investigation. **2020**, 11, 1196	49

832	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. **2020**, 11, 1258	61
831	COVID-19 Usurps Host Regulatory Networks. **2020**, 11, 1278	14
830	The Enigma of Endothelium in COVID-19. **2020**, 11, 989	40
829	COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. **2020**, 28, 1153-1161	62
828	Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A´Review on Neurobiological Insight of the Pandemic. **2020**, 57, 4921-4928	12
827	Novel Insights into the Transmission of SARS-CoV-2 Through the Ocular Surface and its Detection in Tears and Conjunctival Secretions: A Review. **2020**, 37, 4086-4095	19
826	Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes. **2020**, 147, 88-91	14
825	SARS-CoV-2 Receptor Is Enriched in a Subpopulation of Mouse Tongue Epithelial Cells in Nongustatory Papillae but Not in Taste Buds or Embryonic Oral Epithelium. **2020**, 3, 749-758	29
824	Screening the General Population for SARS-CoV-2 Virus and COVID-19 Antibodies: A Counterargument. **2020**, 5, 1107-1110	5
823	Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue. **2020**, 13, 1048-1054	13
822	Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development. **2020**, 3, 65	80
821	Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. **2020**, 21,	49
820	COVID-19 Is a Multifaceted Challenging Pandemic Which Needs Urgent Public Health Interventions. **2020**, 8,	17
819	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. **2020**, 94, 4037-4041	7
818	Role of probiotics to combat viral infections with emphasis on COVID-19. **2020**, 104, 8089-8104	62
817	A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. **2020**, 28, 1141-1152	28
816	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. **2020**, 1, e245-e253	270
815	Animal and translational models of SARS-CoV-2 infection and COVID-19. **2020**, 13, 877-891	106

814	Comparison of nonhuman primates identified the suitable model for COVID-19. **2020**, 5, 157	122
813	Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications. **2020**, 9, 121-124	8
812	A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. **2020**, 12,	143
811	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. **2020**, 94,	113
810	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2. **2020**, 76, 651-661	38
809	Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients. **2020**, 9, e017736	17
808	COVID-19 and Diabetes: What Should We Expect?. **2020**, 14, 1133-1134	4
807	Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. **2020**, 56,	102
806	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. **2020**, 11, 361	115
805	Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2. **2020**, 26, 2054-2063	63
804	Neuroradiologic manifestations of COVID-19: what the emergency radiologist needs to know. **2020** , 27, 737-745	6
803	An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. **2020**, 11, 4207	109
802	Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. **2020**, 117, 22311-22322	267
801	COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. **2020**, 16, e1008762	96
800	Neonatal and Children's Immune System and COVID-19: Biased Immune Tolerance versus Resistance Strategy. **2020**, 205, 1990-1997	12
799	Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. **2020**, 226, 57-69	141
798	Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. **2020**, 9, 1965-1973	26
797	Plasmin Cascade Mediates Thrombotic Events in SARS-CoV-2 Infection via Complement and Platelet-Activating Systems. **2020**, 1, 220-227	1

796	Macrophage activation syndrome and COVID-19. **2020**, 40, 19	58
795	COVID-19-Associated Carotid Atherothrombosis and Stroke. **2020**, 41, 1993-1995	12
794	Resilience of Alzheimer's Disease to COVID-19. **2020**, 77, 67-73	10
793	Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders. **2020**, 7, 515	3
792	Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. **2020**, 12,	38
791	Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. **2020**, 21,	39
790	New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. **2020**, 21,	15
789	Deciphering SARS-CoV-2 Virologic and Immunologic Features. **2020**, 21,	12
788	4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor. **2020**, 21,	9
787	SARS-CoV-2 ORF8 and SARS-CoV ORF8ab: Genomic Divergence and Functional Convergence. **2020**, 9,	22
786	The Sialoside-Binding Pocket of SARS-CoV-2 Spike Glycoprotein Structurally Resembles MERS-CoV. **2020**, 12,	32
785	Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. **2020**, 14, 11821-11830	33
784	Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study. **2021**, 35, 588-597	13
783	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. **2020**, 6, 18	66
782	Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments. **2020**, 11, 595888	23
781	Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19). **2020**, 56,	4
780	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. **2020**, 25,	15
779	Leveraging 3D Model Systems to Understand Viral Interactions with the Respiratory Mucosa. **2020**, 12,	9

778	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. **2020**, 11, 611275	12
777	SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure. **2020**, 9,	16
776	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. **2021**, 74, 1088-1100	22
775	A single dose of recombinant VSV-□-spike vaccine provides protection against SARS-CoV-2 challenge. **2020**, 11, 6402	102
774	Development of vaccines and antivirals for combating viral pandemics. **2020**, 4, 1128-1133	27
773	Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. **2020**, 10, 20250	14
772	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. **2020**, 21, 1470320320979097	3
771	Differences in RAAS/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19. **2020**, 14, 1753944720977715	4
770	A 30-year-old male with COVID-19 presenting with seizures and leukoencephalopathy.. **2020**, 8, 2050313X20977032	7
769	Temporal Profile of Olfactory Dysfunction in COVID-19. **2020**, 4, 2473974X20978133	2
768	Host DDX Helicases as Possible SARS-CoV-2 Proviral Factors: A Structural Overview of Their Hijacking Through Multiple Viral Proteins. **2020**, 8, 602162	10
767	Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies. **2020**, 7, 589060	4
766	COVID-19-Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?. **2020**, 10, 592891	9
765	Rationale for COVID-19 Treatment by Nebulized Interferon-□1b-Literature Review and Personal Preliminary Experience. **2020**, 11, 592543	5
764	Redox Regulation of Microvascular Permeability: IL-1□Potentiation of Bradykinin-Induced Permeability Is Prevented by Simvastatin. **2020**, 9,	0
763	Evidence of SARS-CoV-2 Transcriptional Activity in Cardiomyocytes of COVID-19 Patients without Clinical Signs of Cardiac Involvement. **2020**, 8,	35
762	Virus-Mediated Cell-Cell Fusion. **2020**, 21,	21
761	Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells. **2020**, 18,	12

760	SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. **2020**, 12,	18
759	Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease. **2020**, 18, 140-140	11
758	In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform. **2020**, 21, 527	17
757	Extracellular RNA as a Versatile DAMP and Alarm Signal That Influences Leukocyte Recruitment in Inflammation and Infection. **2020**, 8, 619221	15
756	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. **2020**, 7, 602183	13
755	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. **2020**, 11, 569760	12
754	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). **2020**, 11, 571481	28
753	Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity. **2020**, 11, 586111	14
752	NF-Β Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. **2020**, 11, 598444	66
751	Public Database-Driven Insights Into Aging Stress-Associated Defective Gut Barrier With Low SARS-CoV-2 Receptors. **2020**, 7, 606991	
750	Surveying the Side-Chain Network Approach to Protein Structure and Dynamics: The SARS-CoV-2 Spike Protein as an Illustrative Case. **2020**, 7, 596945	4
749	Deletion of BST2 Cytoplasmic and Transmembrane N-Terminal Domains Results in SARS-CoV, SARS-CoV-2, and Influenza Virus Production Suppression in a Vero Cell Line. **2020**, 7, 616798	4
748	SARS-CoV-2 Is Not Detected in the Cerebrospinal Fluid of Encephalopathic COVID-19 Patients. **2020**, 11, 587384	15
747	Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2. **2020**, 11, 584158	6
746	Physiology of Midkine and Its Potential Pathophysiological Role in COVID-19. **2020**, 11, 616552	3
745	Early Phase Management of the SARS-CoV-2 Pandemic in the Geographic Area of the Veneto Region, in One of the World's Oldest Populations. **2020**, 17,	2
744	Vascular Endothelial Glycocalyx Damage in COVID-19. **2020**, 21,	32
743	Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins. **2020**, 12,	9

742	Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection. **2020**, 1, 801-809	17
741	Immunohistochemical Study of SARS-CoV-2 Viral Entry Factors in the Cornea and Ocular Surface. **2020**, 39, 1556-1562	32
740	Renal complications in coronavirus disease 2019: a systematic review. **2020**, 40, 31	11
739	A bioinformatics analysis on the potential role of ACE2 in cardiac impairment of patients with coronavirus disease 2019. **2020**, 8, 1403	1
738	Whole Genome Identification of Potential G-Quadruplexes and Analysis of the G-Quadruplex Binding Domain for SARS-CoV-2. **2020**, 11, 587829	20
737	Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein. **2020**, 21,	11
736	COVID-19 and cardiovascular disease. **2020**, 32, 263-266	
735	An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. **2020**, 33, 108528	39
734	Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset. **2020**, 11, 596553	23
733	Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. **2020**, 11,	45
732	Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. **2020**, 6,	6
731	Evaluating ELISA, Immunofluorescence, and Lateral Flow Assay for SARS-CoV-2 Serologic Assays. **2020**, 11, 597529	22
730	Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology. **2020**, 2020, 8019360	12
729	Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update. **2020**, 7, 616527	7
728	Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. **2020**, 11, 596631	30
727	Association of Cigarette Smoking, COPD, and Lung Cancer With Expression of SARS-CoV-2 Entry Genes in Human Airway Epithelial Cells. **2020**, 7, 619453	4
726	Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. **2020**, 10,	0
725	Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. **2020**, 12,	5

724	Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route. **2020**, 144, 110243	11
723	The Vagal Autonomic Pathway of COVID-19 at the Crossroad of Alzheimer's Disease and Aging: A Review of Knowledge. **2020**, 4, 537-551	13
722	An analysis of cancer patients with asymptomatic infection of SARS-CoV-2 in a cancer center in Wuhan, China. **2020**, 31, 1420-1422	4
721	Digital Tomosynthesis and COVID-19: An improvement in the assessment of pulmonary opacities. **2020**, 56, 761-763	0
720	Statins in COVID-19: Is there any foundation?. **2020**, 32, 278-281	1
719	SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia. **2020**, 130, 110629	32
718	Don't sugar coat the COVID (only the vasculature). **2020**, 43, 393-398	
717	The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. **2020**, 33, 108488	40
716	Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients. **2020**, 86, 8-14	9
715	Liver transplant immunosuppression during the COVID-19 pandemic. **2020**, 43, 457-463	1
714	Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019. **2020**, 21, 100484	6
713	Sex-Biased Vulnerability of the Heart to COVID-19. **2020**, 95, 2332-2335	9
712	Protein-driven mechanism of multiorgan damage in COVID-19. **2020**, 100069	6
711	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. **2020**, 85, 104510	6
710	COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight?. **2020**, 144, 110231	27
709	Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. **2020**, 1, 100142	76
708	How our specialty can contribute and benefit from COVID-19 research. **2020**, 10, 1274-1275	
707	COVID-19, microthromboses, inflammation, and platelet activating factor. **2020**, 46, 927-933	25

706	Higher COVID-19 risk for patients with cancer. **2020**, 1, 418	1
705	Genetic architecture of host proteins involved in SARS-CoV-2 infection. **2020**, 11, 6397	22
704	Interpretation of SARS-CoV-2 behaviour on different substrates and denaturation of virions using ethanol: an atomic force microscopy study.. **2020**, 10, 44079-44086	5
703	Host-Viral Interactions Revealed among Shared Transcriptomics Signatures of ARDS and Thrombosis: A Clue into COVID-19 Pathogenesis. **2020**, 4, e403-e412	5
702	COVID-19;-The origin, genetics,and management of the infection of mothers and babies. **2020**, 7, 371-388	
701	Chasing COVID-19 through SARS-CoV-2 spike glycoprotein. **2020**, 31, 1-9	7
700	Utilizing microbiome approaches to assist source tracking, treatment and prevention of COVID-19: Review and assessment. **2020**, 18, 3615-3622	6
699	Renin–Angiotensin–Aldosterone System as an Old New Target in Heart Failure Therapy. **2023**, 307-330	0
698	Pathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas. **2023**, 12, 262	2
697	Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses. **2023**, 15, 228	0
696	Design of a multi-epitope-based vaccine consisted of immunodominant epitopes of structural proteins of SARS-CoV-2 using immunoinformatics approach.	0
695	The Complex Interplay between Serum Testosterone and the Clinical Course of Coronavirus Disease 19 Pandemic: A Systematic Review of Clinical and Preclinical Evidence. 41,	0
694	Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. **2023**, 102189	0
693	Urokinase System in Pathogenesis of Pulmonary Fibrosis: A Hidden Threat of COVID-19. **2023**, 24, 1382	0
692	Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations. **2023**, 13,	1
691	Integrated Data Analysis Uncovers New COVID-19 Related Genes and Potential Drug Re-Purposing Candidates. **2023**, 24, 1431	0
690	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. **2023**, 19, e1011063	0
689	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.	0

688	Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform. **2023**, 105944	2
687	Humoral immunity for durable control of SARS-CoV-2 and its variants. **2023**, 43,	0
686	Biphenyl furanocoumarin compounds inhibit SARS-CoV-2 spike pseudovirus infection by binding ACE2.	0
685	New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination.	0
684	Estimated prevalence and trends in smoking among adolescents in South Korea, 2005–2021: a nationwide serial study.	0
683	Teaching vaccine development in schools: Learnings from a survey and curriculum design for a course. 7,	0
682	Hydroxychloroquine: Chemistry and Medicinal Applications. **2023**, 106,	0
681	Regulation of ACE2 isoforms by type 2 inflammation and viral infection in human airway epithelium. **2023**,	0
680	Endothelial dysfunction in patients with COVID-19 is a key mechanism for the development of complications. **2023**, 19, 37-44	0
679	TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection. **2023**, 15, 271	1
678	Intensive Care during the COVID-19 Pandemic. **2023**, 11, 125	0
677	SARS-CoV-2 variant biology: immune escape, transmission and fitness.	1
676	Atemlos nach Corona Dysfunktionale Atmung bei Long Covid. **2023**, 21, 48-52	0
675	SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation. **2023**, 14,	2
674	6-Shogaol Exhibits Anti-viral and Anti-inflammatory Activity in COVID-19-Associated Inflammation by Regulating NLRP3 Inflammasomes. **2023**, 8, 2618-2628	1
673	Post-COVID syndrome.	1
672	A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics.	0
671	Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test.	0

670	Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein. **2023**, 115118	0
669	Toxicity and therapeutic applications of citrus essential oils (CEOs): a review. **2023**, 26, 301-326	2
668	Acute-on-chronic liver failure in patients with severe acute respiratory syndrome coronavirus 2 infection. 15, 41-51	3
667	Heart rate variability as an indicator of COVID-19 induced myocardial injury: a retrospective cohort study. **2023**, 23,	0
666	The oral manifestations and related mechanisms of COVID-19 caused by SARS-CoV-2 infection. 16,	0
665	Acute liver injury in a COVID-19 infected woman with mild symptoms: A case report. 11, 472-478	0
664	COVID-19 VaccinesÂ All You Want to Know. **2023**, 44, 143-172	1
663	The rapid and highly parallel identification of antibodies with defined biological activities by SLISY. **2023**, 14,	0
662	Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions. **2023**, e12890	0
661	Cutaneous manifestations of COVID -19 and COVID -19 vaccination.	1
660	Lipopolysaccharide aggravates canine influenza a (H3N2) virus infection and lung damage via mTOR/autophagy in vivo and in vitro. **2023**, 172, 113597	0
659	Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract. **2023**, 132, 40-53	1
658	COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. **2023**, 16, 233-249	0
657	From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. **2023**, 158, 114208	0
656	Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases. **2023**, 3, 100402	0
655	Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors. **2023**, 561, 111403	0
654	SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development. **2023**, 159, 114242	0
653	Investigating the possible mechanisms of autonomic dysfunction post-COVID-19. **2023**, 245, 103071	1

652	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. **2023**, 37, e00780	0
651	Comparative In-Silico Molecular Docking of Silymarin for SARS-CoV-2 Receptor. **2022**, 2, 58-67	0
650	New method of sterilization and disinfection of objects infected with COVID 19 and prototype test. **2022**, 7, 279-292	0
649	Omicron. **2023**, 367-413	0
648	Profiling ACE2 and TMPRSS2 expression in sinonasal mucosa. **2022**, 8, 020-026	0
647	SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. **2023**, 56, 157-168	2
646	Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. **2022**,	0
645	Efficacy and safety of Qi and Blood Tonic Chinese Medicines in the treatment of COVID-19: A protocol for systematic review and meta-analysis. **2022**, 101, e32136	0
644	S-PDB: Analysis and Classification of SARS-CoV-2 Spike Protein Structures. **2022**,	0
643	Effects of in Utero SARS-CoV-2 Exposure on Newborn Health Outcomes. **2023**, 3, 15-27	1
642	The Effects of COVID-19 Pandemic and Lockdown on Pediatric Nutritional and Metabolic Diseases: A Narrative Review. **2023**, 15, 88	2
641	Androgen deprivation therapy and hormonal status in men with COVID-19. **2023**, 10, 141-154	0
640	Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. **2022**, 17, e0278963	0
639	The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trial. **2022**, 22,	0
638	Identification and quantitative analysis of bioactive components from Potentilla kleiniana Wight et Arn with anti HIV-1 proteases activity. 1-4	0
637	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity.	0
636	Right atrial thrombus, junctional tachycardia, and critical lower limb ischemia: three rare complications of severe acute respiratory syndrome coronavirus 2 infection. 583-591	0
635	Tissue protective role of Ganetespib in SARS-CoV-2-infected Syrian golden hamsters.	0

634	Incursions by severe acute respiratory syndrome coronavirus-2 on the host anti-viral immunity during mild, moderate, and severe coronavirus disease 2019 disease. 794-811	0
633	The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development.	0
632	Pharmacologic Therapeutics for COVID-19. **2023**, 290-318	0
631	In vitro infection of human ocular tissues by SARS-CoV-2 lineage A isolates. **2022**, 22,	0
630	Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial. **2023**, 12, 142	0
629	Multiformin-Type Azaphilones Prevent SARS-CoV-2 Binding to ACE2 Receptor. **2023**, 12, 83	0
628	COVID-19: Risk Stratification. **2023**, 149-164	0
627	Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies. **2023**, 11, 85	0
626	A second update on mapping the human genetic architecture of COVID-19.	0
625	Previous infection with SARS-CoV-2 impacts embryo morphokinetics but not clinical outcomes in a time-lapse imaging system.	0
624	Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence. **2023**, 13, 40	0
623	COVID-19: Inpatient Management. **2023**, 182-232	0
622	Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. **2023**, 11, 58	0
621	The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. **2023**, 15, 95	0
620	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. **2023**, 11, 42	0
619	An immobilization-based, loop-mediated isothermal amplification device for nucleic acid detection of SARS-CoV-2 N gene. **2022**, 36, 838-847	0
618	Emerging Dominant SARS-CoV-2 Variants. **2023**, 63, 335-342	5
617	Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series. **2023**, 15, 102	0

616	Severe SARS-CoV-2 Infection With Multiorgan Involvement Followed by MIS-C in an Adolescent. **2022**, 29, 155	0
615	Effect of physical activity on COVID-19 and underlying mechanisms. 2,	0
614	Spike substitution T813S increases Sarbecovirus fusogenicity by enhancing the usage of TMPRSS2.	0
613	Thorectidiol A Isolated from the Marine Sponge Dactylospongia elegans Disrupts Interactions of the SARS-CoV-2 Spike Receptor Binding Domain with the Host ACE2 Receptor.	0
612	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. **2023**, 12, 177	0
611	Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?. **2023**,	0
610	Defining neutralization and allostery by antibodies against COVID-19 variants.	0
609	Blood-brain barrier disruption in Long COVID-associated cognitive impairment.	0
608	SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2. **2023**, 15, 360	0
607	Assessment of the Prevalence and Incidence of COVID-19 in Saudi Arabia. Volume 16, 227-236	0
606	Links between COVID-19 and Parkinson disease/Alzheimer disease: reciprocal impacts, medical care strategies and underlying mechanisms. **2023**, 12,	1
605	Coronavirus disease 2019 and severe asthma. Publish Ahead of Print,	0
604	Viral infection and its management. **2023**, 189-207	0
603	Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity. **2023**, 15, 309	0
602	Safety, Biodistribution, and Dosimetry Study of Meplazumab, a Potential COVID-19 Therapeutic Drug, with 131I-Labeling and SPECT Imaging.	0
601	COVID-19, Obesity and Bariatric Surgery. **2023**, 1463-1473	0
600	Genetic predisposition to COVID-19 and post-COVID syndrome. **2023**, 173-184	0
599	Coronavirus infection in chemosensory cells.	0

598	Innate immune responses in COVID-19. **2023**, 63-128	0
597	COVID-19 phenomics. **2023**, 191-218	0
596	In-silicoAnalysis of SARS-Cov2 Spike Proteins of Different Field Variants.	0
595	Transmissible Gastroenteritis Virus: An Update Review and Perspective. **2023**, 15, 359	2
594	Ocular Symptoms Associated with COVID-19 Are Correlated with the Expression Profile of Mouse SARS-CoV-2 Binding Sites. **2023**, 15, 354	0
593	Sex and ABO Blood Differences in SARS-CoV-2 Infection Susceptibility. **2023**, 10, 22-26	0
592	Altered host protease determinants for SARS-CoV-2 Omicron. **2023**, 9,	0
591	A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection. **2023**, 95,	0
590	Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.	0
589	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics.	0
588	Blood pH and COVID-19.	0
587	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. **2023**, 19, e1011085	0
586	A retrospective study on prevalence and profile of reverse transcriptase polymerase chain reaction positive severe acute respiratory syndrome corona virus 2 samples tested in a tertiary care hospital, South India. **2023**, 0	0
585	Dissecting Platelet Role in Viral Infection: A Double-Edged Effector of the Immune System. **2023**, 24, 2009	0
584	SARS-CoV-2 Possible Etiology of Cerebral Venous Thrombosis in a Teenager: Case Report and Review of Literature. **2023**, 15, 405	0
583	Transcriptomic approaches in COVID-19: From infection to vaccines. **2023**, 125-144	0
582	miRNAomics in COVID-19. **2023**, 145-160	0
581	Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus. 13,	0

580	The gastrointestinal tract is the gate of entrance for COVID-19. **2023**, 152-156	0
579	Strong Association Between Angiotensin-Converting Enzyme Gene InDel Polymorphism and COVID-19 Diseases. **2023**,	0
578	Revealing the Molecular Interactions between Human ACE2 and the Receptor Binding Domain of the SARS-CoV-2 Wild-Type, Alpha and Delta Variants. **2023**, 24, 2517	1
577	A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19). **2023**, 11, 295	0
576	A Case of Acute Severe Ulcerative Colitis Triggered by COVID-19 Infection. **2023**,	0
575	Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry. **2023**, 19, e1011131	1
574	Epitope-directed anti-SARS-CoV -2 scFv engineered against the key spike protein region could block membrane fusion.	0
573	Atherosclerosis, Cardiovascular Disorders and COVID-19: Comorbid Pathogenesis. **2023**, 13, 478	2
572	SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. **2023**, 15, 632	1
571	Antiviral effects and tissue exposure of tetrandrine against SARS-CoV-2 infection and COVID-19. **2023**, 4,	0
570	Nuclear translocation of spike mRNA and protein is a novel feature of SARS-CoV-2. 14,	0
569	COVID-19 and atrial fibrillation: Intercepting lines. 10,	0
568	A Supine Position and Dual-Dose Applications Enhance Spray Dosing to the Posterior Nose: Paving the Way for Mucosal Immunization. **2023**, 15, 359	0
567	Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment. 1-15	0
566	Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.	0
565	Menstrual Irregularities Post-COVID-19 Infection/Vaccination in Indian Population. **2023**, 14, 694-699	0
564	SARS-CoV-2-free residual proteins mediated phenotypic and metabolic changes in peripheral blood monocytic-derived macrophages in support of viral pathogenesis. **2023**, 18, e0280592	0
563	Epigenetic modifications and regulation in infection. **2023**, 181-209	0

562	SARS-CoV-2 spike and ACE2 entanglement-like binding. **2023**, 5,	0
561	Interaction of copper potential metallodrugs with TMPRSS2: A comparative study of docking tools and its implications on COVID-19. 11,	0
560	COVID-19: Diabetes Perspective Pathophysiology and Management. **2023**, 12, 184	1
559	COVID-19 in childhood and phenotypes of pediatric inflammatory multisystem syndrome. **2023**, 91-100	0
558	Gut microbiome and COVID-19. **2023**, 263-277	0
557	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy.	0
556	Bromhexine: Into the spotlight. **2023**, 719-731	0
555	Dietary factors influencing the COVID-19 epidemic process. **2023**, 15, 463-471	0
554	Effects of previous exposure to different medications on the clinical course of COVID-19 patients in Istanbul, Turkey. **2023**, 7, 79-85	0
553	Modulation of NBAS-Related Functions in the Early Response to SARS-CoV-2 Infection. **2023**, 24, 2634	0
552	An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment. **2023**,	0
551	Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics. **2023**, 51, 030006052311537	0
550	Vitamin D and estrogen steroid hormones and their immunogenetic roles in Infectious respiratory (TB and COVID-19) diseases. **2023**, 46,	0
549	Omics approaches in COVID-19: An overview. **2023**, 3-21	0
548	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. **2023**, 237-262	0
547	Semen parameters and male reproductive potential are not adversely affected after three or more months of recovery from COVID-19 disease. 4,	0
546	SARS-CoV-2 variant-related abnormalities detected by prenatal MRI: a prospective case control study. **2023**, 100587	0
545	Novel coronavirus infection and pregnancy: features of the course of gestation and the possibility of predicting the progression of COVID-19 severity in pregnant women. **2023**, 23, 30	0

544	Crohn disease and COVID-19: points of contact. **2023**, 242-246	0
543	Unveiling the prevalence and impact of diabetes on COVID-19. **2023**, 287-301	0
542	Targeting TLR-4 Signaling to Treat COVID-19-induced Acute Kidney Injury. 0976500X2211477	0
541	Applications of genetic engineering in COVID-19. **2023**, 219-237	0
540	Comparison of COVID-19 Outcomes With Alpha-1 Antitrypsin Deficiency Prevalence in Europe: A Cross-Sectional Study. **2023**,	0
539	Impact of COVID-19 vaccination in post-COVID cardiac complications. **2023**,	0
538	The OM-85 bacterial lysate: A new tool against SARS-CoV-2?. 18,	0
537	Survival-based CRISPR genetic screens across a panel of permissive cell lines identify common and cell-specific SARS-CoV-2 host factors. **2023**, 9, e12744	0
536	Effect of continuing the use of renin angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis. **2023**, 23,	1
535	Prognostic biomarkers for cardiovascular injury in patients with COVID-19: a review. **2023**, 13, 14-23	0
534	The effect of COVID-19 on patients with preexisting autoimmune diseases. **2023**, 495-528	0
533	Effect of polymorphism in Rhinolophus affinis ACE2 on entry of SARS-CoV-2 related bat coronaviruses. **2023**, 19, e1011116	0
532	Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19. **2023**, 543-568	0
531	In silico disease modeling for COVID-19. **2023**, 291-299	0
530	Currently available COVID-19 management options. **2023**, 111-124	0
529	Sex and diet, but not exercise, alter cardiovascular ACE2 and TMPRSS2 mRNA levels in aortic banded swine.	0
528	Role of natural products in infectious diseases. **2023**, 757-770	0
527	Agent-based modeling and phylogenetic analysis suggests that COVID-19 will remain a low-severity albeit highly transmissible disease.	0

526	Higher Angiotensin I Converting Enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.	0
525	Epididymitis, orchitis, and epididymo-orchitis associated with SARS-CoV-2 infection in pediatric patients: A systematic review. 2,	0
524	Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future. **2023**, 24, 1923	0
523	A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.	0
522	An emerging natural antioxidant therapy for COVID-19 infection patients: Current and future directions.	0
521	Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.	0
520	Innate immune recognition against SARS-CoV-2. **2023**, 43,	1
519	Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate.	0
518	Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective. **2023**, 13,	0
517	Evaluating the Adverse Events Associated with Three Doses of the COVID-19 Vaccination in Adults in the Western Region of Saudi Arabia: A Cross-Sectional Study. **2023**, 11, 266	0
516	Coronaviruses use ACE2 monomers as entry receptors.	0
515	Role of vitamin D in modulating the immune response to SARS-CoV-2 and other coronavirus infections. **2023**, 26, 95	0
514	Comprehensive analysis of SARS-CoV -2 receptor proteins in human respiratory tissues identifies alveolar macrophages as potential virus entry site.	0
513	COVID-19 in Older Adults. **2023**, 1-19	0
512	Enzymatic approaches against SARS-CoV-2 infection with an emphasis on the telomere-associated enzymes.	0
511	Type 2 Immunity and Its Impact on COVID-19 Infection in the Airways. **2023**, 15, 402	0
510	Alterations in Gut Microbiota Composition in Patients with COVID-19: A Pilot Study of Whole Hypervariable 16S rRNA Gene Sequencing. **2023**, 11, 367	1
509	The lung employs an intrinsic surfactant-mediated inflammatory response for viral defense.	0

508	Association of SARS-CoV-2 viral load with biochemical profile of COVID-19 patients: A nigerian experience. **2023**, 26, 109	0
507	Hospitalizations and deaths of children and adolescents with Severe Acute Respiratory Infection due to COVID-19 during the epidemiological year of 2020. 65,	0
506	Viral Invasion Flow-Chart for Pathogens With Replication Target in a Host Cell. **2023**, 33-53	0
505	The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5 Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung Microvascular Endothelial Cells. **2023**, 15, 332	0
504	Viruses and Endocrine Diseases. **2023**, 11, 361	0
503	Safety and efficacy of glucocorticoids in the treatment of COVID-19: A meta-analysis of randomized control trials.	0
502	Association of combustible cigarettes and heated tobacco products use with SARS-CoV-2 infection and severe COVID-19 in Japan: a JASTIS 2022 cross-sectional study. **2023**, 13,	0
501	Semen quality changes during infection and recovery phases of mild-to-moderate COVID-19 in reproductive-aged patients: a prospective case series. **2023**, 33,	0
500	A review article on neuroprotective, immunomodulatory, and anti-inflammatory role of vitamin-D3 in elderly COVID-19 patients. **2023**, 59,	0
499	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. **2023**, 13, 559	1
498	Tissue distribution of angiotensin-converting enzyme 2 (ACE2) receptor in wild animals with a focus on artiodactyls, mustelids and phocids. **2023**, 16, 100492	0
497	The role of spike protein entry inhibitors in the treatment of mild-to-moderate covid-19 in nonhospitalized patients. **2022**, 9, 52-59	0
496	Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study (Preprint).	0
495	Therapeutic Potential of Nitric Oxide in the Management of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS). **2023**, 249-258	0
494	Predictive analytics of genetic variation in the COVID-19 genome sequence: a data science perspective. **2023**, 229-247	0
493	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,	0
492	Cellular mechanisms of transcriptional regulation of human cell lines exposed to cadmium-based quantum dots. **2023**, 10, 1177-1189	0
491	Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2. **2023**, 13, 8779-8793	0

490	Virtual Screening for SARS-COV-2 Entry Inhibitors by Dual Targeting of TMPRSS2 and CTSL. **2023**, 14, 9-18	0
489	Study immunity and genetic in Covid 19. **2023**,	0
488	Angiotensin in the gut. **2023**, 669-679	0
487	Immune Factors Drive Expression of SARS-CoV-2 Receptor Genes Amid Sexual Disparity. **2023**, 15, 657	0
486	ACE2 in pulmonary diseases. **2023**, 285-316	0
485	Morphological aspect of the angiotensin-converting enzyme 2. **2023**, 389-417	0
484	Angiotensin and COVID-19. **2023**, 473-489	0
483	Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19. **2023**, 109, 109-111	0
482	Mechanisms of SARS-CoV-2 Inactivation using UVC Laser Radiation.	0
481	Chronic alcohol consumption and COVID -19 infection risk: A narrative review.	0
480	SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design.	2
479	STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2. **2023**, 23, 2593-2600	0
478	Diversity of immune responses in children highly exposed to SARS-CoV-2. 14,	0
477	SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. **2023**, 42, 112189	0
476	Identification of the regulatory mechanism of ACE2 in COVID-19-induced kidney damage with systems genetics approach. **2023**, 101, 449-460	0
475	CuMV VLPs Containing the RBM from SARS-CoV-2 Spike Protein Drive Dendritic Cell Activation and Th1 Polarization. **2023**, 15, 825	0
474	Genome-scale CRISPR-Cas9 screen identifies novel host factors as potential therapeutic targets for SARS-CoV-2 infection.	0
473	Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types.	0

472	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. **2023**, 29,	0
471	THE EFFECT OF THE PRESENCE OF FRAGMENTED QRS IN THE ECG ON THE LENGTH OF STAY IN INTENSIVE CARE UNIT AND MORTALITY IN INTENSIVE CARE COVID-19 PATIENTS. **2023**, 24, 201-205	0
470	New insights into how popular electronic cigarette aerosols and aerosol constituents affect SARS-CoV-2 infection of human bronchial epithelial cells. **2023**, 13,	0
469	Microbiota-derived short chain fatty acids: Their role and mechanisms in viral infections. **2023**, 160, 114414	0
468	Endogenous IFITMs boost SARS-coronavirus 1 and 2 replication whereas overexpression inhibits infection by relocalizing ACE2. **2023**, 26, 106395	0
467	Structural and Physiological Changes of the Kidney with Age and its Impact on Chronic Conditions and COVID-19. **2023**, 101932	0
466	nanoCLAMP potently neutralizes SARS-CoV-2 and protects K18-hACE2 mice from infection.	0
465	Long COVID-19 and viral fibromyalgia-ness Suggesting a mechanistic role for fascial myofibroblasts (Nineveh, the shadow is in the fascia). 10,	0
464	Identifying environmental risk factors for post-acute sequelae of SARS-CoV-2 infection: An EHR-based cohort study from the recover program. **2023**, 11, 100352	0
463	SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.	0
462	Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. **2023** , 127, 66-81	0
461	Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME. **2023**, 13,	0
460	Intranasal soluble ACE2 improves survival and prevents brain SARS-CoV-2 infection. **2023**, 6, e202301969	0
459	Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions. **2023**, 20,	0
458	Seroprevalence of SARS-CoV-2 in hospital workers in the southern region of Minas Gerais state in Brazil: An analysis of the pre-vaccine period.	0
457	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. **2023**, 11, 1015	0
456	Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management. **2023**, 15, 225-243	0
455	Veklury ′(remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether- cyclodextrin content.	0

454	Adipokines in obesity and metabolic-related-diseases. **2023**,	0
453	Density estimation of SARS-CoV2 spike proteins using super pixels segmentation technique. **2023**, 138, 110210	0
452	Is intestinal transport dysfunctional in COVID-19-related diarrhea?. **2023**, 324, G415-G418	0
451	Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants. **2023**, 213, 105587	0
450	Inflammasome genes polymorphisms are associated with progression to mechanical ventilation and death in a cohort of hospitalized COVID-19 patients in a reference hospital in Rio de Janeiro, Brazil. **2023**, 865, 147325	0
449	The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. **2023**, 213, 105590	0
448	Burgeoning therapeutic strategies to curb the contemporary surging viral infections. **2023**, 179, 106088	0
447	FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms. **2023**, 162, 114614	0
446	Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. **2023**, 152, 1-21	0
445	In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. **2023**, 91, 104561	0
444	Genetic susceptibility to severe COVID-19. **2023**, 110, 105426	0
443	The role of Ca2+ signalling in the pathology of exocrine pancreas. **2023**, 112, 102740	0
442	Neutralization of the new coronavirus by extracting their spikes using engineered liposomes. **2023**, 50, 102674	0
441	Molecularly imprinted miniature electrochemical biosensor for SARS-CoV-2 spike protein based on Au nanoparticles and reduced graphene oxide modified acupuncture needle. **2023**, 151, 108375	2
440	Development of SARS-CoV-2 neutralizing antibody detection assay by using recombinant plant-produced proteins. **2023**, 38, e00796	0
439	Chromatographic impurity profile assessment of dual action binary combination: Ecological analysis with comparative statistics. **2023**, 33, 101075	0
438	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. **2023**, 28, 103579	0
437	A systematic review on immunity functionalities and nutritional food recommendations to develop immunity against viral infection. **2023**, 3, 100291	0

436	Development and applications of mRNA treatment based on lipid nanoparticles. **2023**, 65, 108130	0
435	Metallo-antiviral aspirants: Answer to the upcoming virus outbreak. **2023**, 8, 100104	0
434	The severity of COVID-19 in hypertensive patients is associated with mirSNPs in the 3? UTR of ACE2 that associate with miR-3658: In silico and in ́vitro studies. **2023**, 18, 1030-1047	0
433	Decoding the bidirectional relationship between gut microbiota and COVID-19. **2023**, 9, e13801	0
432	Platelet Ⅱb Ⅲ integrin binds to SARS-CoV-2 spike protein of alpha strain but not wild type and omicron strains. **2023**, 657, 80-85	0
431	Applications of deep learning in single-cell analysis.	0
430	ANALYSIS OF CLINICAL AND FUNCTIONAL INDICES OF CARDIOVASCULAR SYSTEM IN POST-COVID-19 EMERGENCY WORKERS OF THE CHORNOBYL ACCIDENT. **2022**, 27, 290-306	0
429	Interaction of Anti-COVID-19 Drugs with Cardiovascular Therapy. **2022**, 255-261	0
428	Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy. **2023**, 79, 111-121	1
427	Electrical biosensing system utilizing ion-producing enzymes conjugated with aptamers for the sensing of severe acute respiratory syndrome coronavirus 2. **2023**, 39, 100549	1
426	Spatial shifting of COVID-19 clusters and disease association with environmental parameters in India: A time series analysis. **2023**, 222, 115288	0
425	Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents. **2023**, 31, 370-382	0
424	The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19. 2,	0
423	Thymus vulgaris, a natural pharmacy against COVID-19: A molecular review. **2023**, 38, 100635	1
422	The development of COVID-19 treatment. 14,	2
421	Drug delivery as a sustainable avenue to future therapies. **2023**, 354, 746-754	0
420	The Role of the Plasminogen/Plasmin System in Inflammation of the Oral Cavity. **2023**, 12, 445	0
419	Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA. 13,	0

418	Role of Sex and Age in Fatal Outcomes of COVID-19: Women and Older Centenarians Are More Resilient. **2023**, 24, 2638	0
417	Epigenetic Targets and Pathways Linked to SARS-CoV-2 Infection and Pathology. **2023**, 11, 341	0
416	Hydrocephalus As Possible Prodromal Manifestation of COVID-19: A Report of Two Cases. **2023**,	0
415	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. **2023**, 9, e13285	0
414	SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction. **2023**, 6,	0
413	Susceptibility of domestic and companion animals to SARS-CoV-2: a comprehensive review. **2023**, 55,	0
412	Mucociliary Clearance Augmenting Drugs Block SARS-Cov-2 Replication in Human Airway Epithelial Cells.	0
411	Structural prediction of chimeric immunogens to elicit targeted antibodies against betacoronaviruses.	0
410	Chronological changes of viral shedding in adult inpatients with Omicron infection in Shanghai, China. 14,	0
409	Exploring the Protective Effect of Food Drugs against Viral Diseases: Interaction of Functional Food Ingredients and SARS-CoV-2, Influenza Virus, and HSV. **2023**, 13, 402	3
408	Differential haplotype expression in class I MHC genes during SARS-CoV-2 infection of human lung cell lines. 13,	0
407	Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. **2023**, 33, 188-202	0
406	High-depth sequencing characterization of viral dynamics across tissues in fatal COVID-19 reveals compartmentalized infection. **2023**, 14,	0
405	Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice. **2023**, 8,	0
404	Angiotensin-converting enzyme 2□t the heart of the COVID-19 pandemic. **2023**, 186, 906-922	0
403	Liver injury associated with the severity of COVID-19: A meta-analysis. 11,	0
402	Interactions between Humans and Dogs during the COVID-19 Pandemic: Recent Updates and Future Perspectives. **2023**, 13, 524	0
401	Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2.	0

400	Angiotensin II increases respiratory rhythmic activity in the preBötzinger complex without inducing astroglial calcium signaling. 17,	0
399	Thyroid storm in a pregnant woman with COVID-19 infection: A case report and review of literatures. 11, 888-895	0
398	Periodontitis and COVID-19: Immunological Characteristics, Related Pathways, and Association. **2023**, 24, 3012	0
397	Co-infection associated with SARS-CoV-2 and their management. **2022**, 8,	2
396	Urological complications of COVID-19: a systematic review. **2023**, 49, 24-40	0
395	Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (Mpro) by using STD-NMR spectroscopy, in silico studies and antiviral assays. **2023**, 234, 123540	0
394	LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein. **2023**, 21, e3001959	1
393	Vitamin D Deficiency: An Underestimated Factor in Sepsis?. **2023**, 24, 2924	0
392	Specialized pro-resolving lipid mediators regulate inflammatory macrophages: A paradigm shift from antibiotics to immunotherapy for mitigating COVID-19 pandemic. 10,	0
391	Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells. **2023**, 211, 105550	0
390	Comparison of truncated human angiotensin-converting enzyme 2 (hACE2) expression in pET28a(+) versus pET-SUMO vector and two Escherichia coli strains. **2023**, 68, 61-70	0
389	Appearance of extrapyramidal symptoms in adolescent psychiatry patients during COVID-19 infection. **2023**, 95,	0
388	Green synthesis, Single-Crystal X-RD, Hirshfeld Analysis and Anti-Covid-19 Molecular Docking Investigation of Symmetrical Azines. **2023**, 8,	0
387	A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site. **2023**, 11, 371	0
386	Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. **2023**, 15, 432	0
385	Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. **2023**, 21, e3001989	0
384	Computational design of candidate multi-epitope vaccine against SARS-CoV-2 targeting structural (S and N) and non-structural (NSP3 and NSP12) proteins. 1-20	0
383	SARS-CoV-2 infection of intestinal epithelia cells sensed by RIG-I and DHX-15 evokes innate immune response and immune cross-talk. 12,	0

382	Exploring the potential mechanisms of impairment on genitourinary system associated with coronavirus disease 2019 infection: Bioinformatics and molecular simulation analyses. **2023**,	0
381	Impact of omalizumab therapy on the course of COVID-19 in a patient with severe asthma: A case report. 1-5	0
380	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. **2023**, 24, 3255	0
379	A Monoclonal Human Alveolar Epithelial Cell Line (A[illegible]) with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections. **2023**, 10,	0
378	Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein. **2023**, 21, 1550-1556	0
377	Protease-Responsive Potential-Tunable AIEgens for Cell Selective Imaging of TMPRSS2 and Accurate Inhibitor Screening. **2023**, 95, 3789-3798	0
376	Potential antiviral effects of pantethine against SARS-CoV-2. **2023**, 13,	0
375	Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells. **2023**, 24, 3288	0
374	In silico analysis reveals hypoxia-induced miR-210-3p specifically targets SARS-CoV-2 RNA. 1-23	0
373	Ferritin and procalcitonin in COVID-19 associated acute kidney injury [illegible]gender disparities, but similar outcomes. **2023**, 31, 35-42	0
372	SARS-CoV-2 infection of kidney tissues from severe COVID-19 patients. **2023**, 95,	1
371	Autoimmunity, COVID-19 Omicron Variant, and Olfactory Dysfunction: A Literature Review. **2023**, 13, 641	0
370	Androgen receptor, a possible anti-infective therapy target and a potent immune respondent in SARS-CoV-2 spike binding: a computational approach. **2023**, 21, 317-327	1
369	Relationship between severe acute respiratory syndrome coronavirus 2 and diabetes mellitus (review). **2023**, 26, 66-74	0
368	Induced Pluripotent Stem Cell-Derived Organoids: Their Implication in COVID-19 Modeling. **2023**, 24, 3459	0
367	Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines. **2023**, 13,	0
366	Suppression of angiotensin converting enzyme 2, a host receptor for SARS-CoV-2 infection, using 5-aminolevulinic acid in vitro. **2023**, 18, e0281399	0
365	HuCoPIA: An Atlas of Human vs. SARS-CoV-2 Interactome and the Comparative Analysis with Other Coronaviridae Family Viruses. **2023**, 15, 492	0

364	Performance characteristics of the boson rapid SARS‐cov‐2 antigen test card vs RT‐PCR: Cross‐reactivity and emerging variants. **2023**, 9, e13642	0
363	SARS-CoV-2 leverages airway epithelial protective mechanism for viral infection. **2023**, 26, 106175	0
362	Outcomes of COVID-19 patients with acute kidney injury and longitudinal analysis of laboratory markers during the hospital stay: A multi-center retrospective cohort experience from Pakistan. **2023**, 102, e32919	0
361	Altered microRNA Transcriptome in Cultured Human Airway Cells upon Infection with SARS-CoV-2. **2023**, 15, 496	0
360	Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. **2023**, 11, 517	0
359	COVID-19 and Its Impact on Onset and Progression of Parkinson's and Cognitive Dysfunction.	0
358	Chronic alcohol intake regulates expression of SARS-CoV2 infection-relevant genes in an organ-specific manner. **2023**, 47, 76-86	2
357	Transferrin Receptor Protein 1 Cooperates with mGluR2 To Mediate the Internalization of Rabies Virus and SARS-CoV-2. **2023**, 97,	0
356	Impact of COVID-19 on Cardiovascular Disease. **2023**, 15, 508	0
355	Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2. **2023**, 21, 1966-1977	0
354	Analytical approaches for determination of COVID-19 candidate drugs in human biological matrices. **2023**, 160, 116964	0
353	A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine. **2023**, 19,	0
352	Cardiovascular complications of the coronavirus disease (COVID-19). **2022**, 8, 6-14	0
351	High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.	0
350	Role of Vitamin D, ACE2 and the Proteases as TMPRSS2 and Furin on SARS-CoV-2 Pathogenesis and COVID-19 Severity. **2023**, 54, 223-230	0
349	Thrombosis and Anticoagulation Strategies in Patients with COVID-19 Including Japanese Perspective. **2023**, 30, 311-320	0
348	How the Competition for Cysteine May Promote Infection of SARS-CoV-2 by Triggering Oxidative Stress. **2023**, 12, 483	0
347	Transcription regulation of SARS-CoV-2 receptor ACE2 by Sp1: a potential therapeutic target.	0

346	Optimal Delivery Management for the Prevention of Early Neonatal SARS-CoV-2 Infection: Systematic review and Meta-analysis.	0
345	Human brain organoids to explore SARS-CoV-2-induced effects on the central nervous system. **2023**, 33,	0
344	P-Selectin promotes SARS-CoV-2 interactions with platelets and the endothelium.	0
343	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). **2023**, 1-15	0
342	The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. **2023**, 12, 329	0
341	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern. **2023**, 9, 393-404	0
340	Alliance of Heart and Endoderm: Multilineage Organoids to Model Co-development. **2023**, 132, 511-518	1
339	Uptake of severe acute respiratory syndrome coronavirus 2 spike protein mediated by angiotensin converting enzyme 2 and ganglioside in human cerebrovascular cells. 17,	0
338	Origin and evolution of SARS-CoV-2. **2023**, 138,	1
337	Hyperinflammatory Response in COVID-19: A Systematic Review. **2023**, 15, 553	0
336	Autonomic heart rate modulation in patients with coronavirus disease 2019 in mechanical ventilation. **2023**, 69, 181-185	0
335	Human Nasal Epithelium Damage as the Probable Mechanism Involved in the Development of Post-COVID-19 Parosmia.	0
334	The Comparison of Retinal Microvascular Findings in Acute COVID-19 and 1-Year after Hospital Discharge Assessed with Multimodal Imaging—A Prospective Longitudinal Cohort Study. **2023**, 24, 4032	0
333	Multi-omics analysis reveals genomic, clinical and immunological features of SARS-CoV-2 virus target genes in pan-cancer. 14,	0
332	SARS-CoV-2-Induced TSLP Is Associated with Duration of Hospital Stay in COVID-19 Patients. **2023**, 15, 556	0
331	Rapidly Adaptable Multiplexed Yeast Surface Display Serological Assay for Immune Escape Screening of SARS-CoV-2 Variants.	0
330	Activation of the Interferon Pathway in Trophoblast Cells Productively Infected with SARS-CoV-2.	0
329	Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. **2023**, 9, e13853	0

328	Plasma proteome dynamics of COVID-19 severity learnt by a graph convolutional network of multi-scale topology. **2023**, 6, e202201624	0
327	SARS-CoV-2 Infection and the Male Reproductive System: A Brief Review. **2023**, 13, 586	0
326	Chemosensory Ability and Sensitivity in Health and Disease: Epigenetic Regulation and COVID-19. **2023**, 24, 4179	0
325	SARS-CoV-2 Affects Both Humans and Animals: What Is the Potential Transmission Risk? A Literature Review. **2023**, 11, 514	0
324	Gastrointestinal and Hepatobiliary Symptoms and Disorders with Long (Chronic) COVID Infection. **2023**, 52, 139-156	0
323	SARS-CoV-2 S Glycoprotein Stabilization Strategies. **2023**, 15, 558	0
322	Melastoma malabathricum L. Suppresses Neutrophil Extracellular Trap Formation Induced by Synthetic Analog of Viral Double-Stranded RNA Associated with SARS-CoV-2 Infection. **2023**, 12, 341	0
321	Potent Therapeutic Strategies for COVID-19 with Single-Domain Antibody Immunoliposomes Neutralizing SARS-CoV-2 and Lip/cGAMP Enhancing Protective Immunity. **2023**, 24, 4068	0
320	In silico analysis of dietary polyphenols and their gut microbial metabolites suggest inhibition of SARS-CoV-2 infection, replication, and host inflammatory mediators. 1-19	0
319	SARS-CoV-2 infection alkalinizes the ERGIC and lysosomes through the viroporin activity of the viral envelope protein. **2023**, 136,	0
318	Diagnostic TR-FRET assays for detection of antibodies in patient samples. **2023**, 3, 100421	0
317	Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches. **2023**, 11, 489	0
316	SARS-CoV-2 infection causes fibrotic pathogenesis through deregulating mitochondrial beta-oxidation.	0
315	Antibody-mediated cell entry of SARS-CoV-2.	0
314	Comparing the Clinical Manifestations of Bell Palsy between Pre-COVID-19 Pandemic and COVID-19 Pandemic Periods. **2023**, 12, 1700	0
313	The paradigm of prophylactic viral outbreaks measures by microbial biosurfactants. **2023**, 16, 575-587	0
312	Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. **2023**,	0
311	Oral manifestations of COVID-19: A review. **2023**, 1-11	0

310	Mucociliary clearance augmenting drugs block SARS-CoV-2 replication in human airway epithelial cells. **2023**, 324, L493-L506	0
309	OligoBinders: Bioengineered Soluble Amyloid-like Nanoparticles to Bind and Neutralize SARS-CoV-2. **2023**, 15, 11444-11457	0
308	Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients. **2023**, 24, 4319	0
307	Investigating the competition between ACE2 natural molecular interactors and SARS-CoV-2 candidate inhibitors. **2023**, 374, 110380	0
306	Molecular mechanisms of human coronavirus NL63 infection and replication. **2023**, 327, 199078	0
305	Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study. 25, e45419	0
304	Ectopic expression of SARS-CoV-2 S and ORF-9B proteins alters metabolic profiles and impairs contractile function in cardiomyocytes. 11,	0
303	Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. **2023**, 19, e1011168	0
302	Cell transplantation for COVID-19 treatment: transmission of stem stomal (mesenchimal) cells. **2020**, 15, 10-19	0
301	Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity. **2023**, 11, 510	0
300	SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants. **2023**, 18, 636-653	0
299	Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. **2023**, 11, 524	0
298	Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. **2023**, 117, 109929	0
297	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. 14,	0
296	[Hypothesis] The protective role of Testosterone in COVID-19.	0
295	Mutation-driven parallel evolution in emergence of ACE2-utilizing sarbecoviruses. 14,	0
294	A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models. **2023**, 11, 526	0
293	Analysis of the SARS-CoV-2 spike protein revealed that blocked receptor-binding domain antigenicity decreases the production of neutralizing antibodies in vivo.	0

292	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401	0
291	Molecular Determinants of the Early Life Immune Response to COVID-19 Infection and Immunization. **2023**, 11, 509	0
290	Infecties (COVID-19). **2022**, 311-323	0
289	In Vitro Pharmacokinetic Behavior of Antiviral 3-Amidinophenylalanine Derivatives in Rat, Dog and Monkey Hepatocytes. **2023**, 11, 682	0
288	Detection of Adverse Drug Reactions in COVID-19 Hospitalized Patients in Saudi Arabia: A Retrospective Study by ADR Prompt Indicators. **2023**, 11, 660	0
287	Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds.	0
286	SARS-CoV-2 pandemics: An update of CRISPR in diagnosis and host□virus interaction studies. **2023**,	0
285	Insights into organoid-based modeling of COVID-19 pathology. **2023**, 20,	0
284	Potential soluble angiotensin-converting enzyme 2 in oral and salivary coronavirus infection therapy. **2022**, 9, 12-15	0
283	Mutating novel interaction sites in NRP1 reduces SARS-CoV-2 spike protein internalization. **2023**, 26, 106274	0
282	Establishment of angiotensin-converting enzyme 2 and cluster of differentiation 147 dual target cell membrane chromatography based on SNAP-tag technology for screening anti severe acute respiratory syndrome coronavirus 2 active components. **2023**, 1693, 463903	0
281	Internal Carotid Artery Dissection With Thrombosis in a Child With Prothrombin Gene Mutation. **2023**,	0
280	Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis. **2023**, 168,	0
279	Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. **2023**, 19,	0
278	Review on the Biogenesis of Platelets in Lungs and Its Alterations in SARS-CoV-2 Infection Patients. **2023**, 2023, 1-10	0
277	The Prevalence of Irritable Bowel Syndrome after Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Their Association: A Systematic Review and Meta-Analysis of Observational Studies. **2023**, 12, 1865	0
276	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. **2023**, 11, 545	0
275	COVID-19 Biogenesis and Intracellular Transport. **2023**, 24, 4523	2

274	Assessment of GO-Based Protein Interaction Affinities in the Large-Scale Human Coronavirus Family Interactome. **2023**, 11, 549	0
273	Association of COVID-19 with Comorbidities: An Update. **2023**, 6, 334-354	0
272	MDTOMO: Continuous conformational variability analysis in cryo electron subtomogram data using flexible fitting based on Molecular Dynamics simulations.	0
271	Nasal sprays for treating COVID-19: a scientific note. **2023**, 75, 249-265	0
270	Pituitary and SARS CoV-2: An unremitting conundrum. **2023**, 101752	0
269	Single-domain antibody for binding the conserved epitope in the SARS-CoV-2 spike protein receptor-binding domain. **2023**,	0
268	Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study. **2023**, 55, 169-175	0
267	Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects. **2023**, 15, 641	0
266	The Latest Cellular and Molecular Mechanisms of COVID-19 on Non-Lung Organs. **2023**, 13, 415	0
265	Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection. **2023**, 11, 612	0
264	Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides. **2023**, 212, 105571	0
263	The Outcome of COVID-19 Infection in Patients With Gastrointestinal Diseases: An Experience at a Tertiary Center. **2023**,	0
262	Bioinformatics analysis based on high-throughput sequencing data to identify hub genes related to different clinical types of COVID-19. **2023**, 23,	0
261	Female reproductive health during the COVID-19 pandemic: latest evidence and understanding.	0
260	Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models. **2023**, 27,	0
259	Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery Genetics Alliance Perspective. **2023**, 66, 3664-3702	0
258	COVID-19 aus Sicht der Gastroenterologie. **2023**, 18, 84-92	0
257	Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization.	1

256	COVID-19: Insights into long-term manifestations and lockdown impacts. **2023**,	0
255	Does the variant positivity and negativity affect the clinical course in COVID-19?: A cohort study. **2023**, 102, e33132	0
254	SARS-CoV-2 Delta (B.1.617.2) variant replicates and induces syncytia formation in human induced pluripotent stem cell-derived macrophages. 11, e14918	0
253	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. **2023**, 161, 117000	0
252	The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges. Volume 19, 103-126	0
251	Interactions between the renin□ngiotensin□ldosterone system and COVID-19. **2023**, 355-373	0
250	The renin-angiotensin system in the eye. **2023**, 419-447	0
249	Using Real-Time PCR Fluorescence Reaction Values to Improve SARS-CoV-2 Virus Detection and Benefit Clinical Decision-Making. **2023**, 13, 683	0
248	Transgenic animal models for the functional analysis of ACE2. **2023**, 491-503	0
247	COVID-19 vaccination and thyroiditis. **2023**, 101759	0
246	Association of ApaI rs7975232 and BsmI rs1544410 in clinical outcomes of COVID-19 patients according to different SARS-CoV-2 variants. **2023**, 13,	0
245	Short-Chain Fatty Acids in the Microbiota□Gut□Brain Axis: Role in Neurodegenerative Disorders and Viral Infections. **2023**, 14, 1045-1062	0
244	Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. **2023**, 70, 13-25	0
243	Persistent olfactory learning deficits during and post-COVID-19 infection. **2023**, 4, 100081	0
242	A Scoping Review on COVID-19-Induced Cardiovascular Complications. **2023**, 3, 348-369	0
241	Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing. **2023**, 9, e14115	0
240	Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. **2023**, 12, 816	0
239	The infectivity of SARS-CoV-2 progeny virions requires the activity of host cell N-myristoyltransferases and it is severely compromised by their inhibition.	0

238	Virologists' Sex- and Gender-Based Medical Knowledge of COVID-19 Affects Quality of Students' Education. **2023**, 4, 118-125	0
237	Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. **2023**, 13, 472	0
236	Understanding COVID-19 in children: immune determinants and post-infection conditions.	0
235	Vitamin C promotes ACE2 degradation and protects against SARS-CoV-2 infection. **2023**, 24,	1
234	Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination. **2023**, 11,	0
233	Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1).	0
232	Investigating antigenic features of the SARS-CoV-2 isolated in Russian Federation in 2021–2022 by hyperimmune mouse serum neutralisation. **2023**, 13, 37-45	0
231	Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice. **2023**, 24,	0
230	Role of the microbiota-gut-brain axis in postacute COVID syndrome. **2023**, 324, G322-G328	0
229	Antiviral Molecular Targets of Essential Oils against SARS-CoV-2: A Systematic Review. **2023**, 91, 15	2
228	Unraveling the Interactions between Human DPP4 Receptor, SARS-CoV-2 Variants, and MERS-CoV, converged for Pulmonary Disorders Integrating through Immunoinformatics and Molecular Dynamics.	0
227	Systematic Guidelines for Effective Utilization of COVID-19 Databases in Genomic, Epidemiologic, and Clinical Research. **2023**, 15, 692	0
226	Deep Learning in COVID-19 Diagnosis, Prognosis and Treatment Selection. **2023**, 11, 1279	0
225	SARS-CoV-2 infection of kidney tissues in some severe and fatal cases of COVID-19. **2023**, 95,	0
224	Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. **2023**, 42, 373-383	1
223	Severe COVID-19versusmultisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection. **2023**, 32, 220197	0
222	Development of Fully Human, Bispecific Antibodies that Effectively Block Omicron Variant Pseudovirus Infections.	0
221	Examining the associations between COVID-19 infection and pediatric type 1 diabetes. 1-9	0

220	Phenome-wide association study to explore the long-term symptoms after infection with novel coronavirus in the UK Biobank.	0
219	Predicting the feasibility of targeting a conserved region on the S2 domain of the SARS-CoV-2 spike protein.	0
218	Immunometabolic rewiring in long COVID patients with chronic headache.	0
217	Neurological manifestations associated with SARS-CoV-2 infection: an updated review.. **2023**, 64, 108-122	0
216	Thyroglobulin levels in COVID-19-positive patients: Correlations with thyroid function tests, inflammatory markers, and glucocorticoid use. 13,	0
215	Rescuing fertility during COVID-19 infection: exploring potential pharmacological and natural therapeutic approaches for comorbidity, by focusing on NLRP3 inflammasome mechanism..	0
214	Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines. **2023**, 11, 615	0
213	Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. **2023**, 55, 471-483	0
212	The impact of the COVID-19 pandemic on semen quality of uninfected men. **2023**, 33,	0
211	A Multiparametric and High-Throughput Platform for Host Virus Binding Screens.	0
210	Early transcriptional responses of human nasal epithelial cells to infection with Influenza A and SARS-CoV-2 virus differ and are influenced by physiological temperature.	0
209	Long-Term Adverse Effects of Mild COVID-19 Disease on Arterial Stiffness, and Systemic and Central Hemodynamics: A Pre-Post Study. **2023**, 12, 2123	0
208	Epidemiology of the Acceptance of Anti COVID-19 Vaccine in Urban and Rural Settings in Cameroon. **2023**, 11, 625	0
207	Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants. **2023**, 4,	0
206	Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike.	0
205	A bibliometric analysis of chronic obstructive pulmonary disease and COVID-19. **2023**, 102, e33240	0
204	Infectious Agents: From the Red Queen Paradigm to Some of Their Genuine Traits. **2023**, 47-107	0
203	Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2. **2023**, 11, 717	0

202	Evaluation of COVID-19 Patients with the Assessment of Selfreported Olfactory Functioning and Olfaction-related Quality of Life Questionnaire. **2023**, 39, 39-43	0
201	Cigarette smoke preferentially induces full length ACE2 expression in differentiated primary human airway cultures but does not alter the efficiency of cellular SARS-CoV-2 infection. **2023**, 9, e14383	0
200	DOENÇAS AUTOIMUNES RELACIONADOS A SÍNDROME DO PÓS-COVID-19: NOVOS DESDOBRAMENTOS DA PANDEMIA. **2023**, 3, 1103-1118	0
199	Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.	0
198	B cell-related tertiary lymphoid structure may exert inhibitory effects on lung adenocarcinoma and SARS-COV-2. **2023**, 9, e14334	0
197	In vitrocomparison of SARS-CoV-2 variants.	0
196	Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in COVID-19. **2023**, 12, 877	0
195	Foetal Intrapartum Compromise at Term: Could COVID-19 Infection Be Involved? A Case Report. **2023**, 59, 552	0
194	Transmission of SARS-CoV-2 from mother to fetus or neonate: What to know and what to do?. **2023** , 101429	0
193	The effect of COVID-19 infection on the menstrual cycle: a cross-sectional investigation in the MENA region. 1-7	0
192	Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients. 14,	0
191	Urine proteomic characterization of active and recovered COVID-19 patients.	0
190	30th Annual GP2A Medicinal Chemistry Conference. **2023**, 16, 432	0
189	COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors. **2023**, 24, 5374	0
188	Sequence analysis of hot spot regions of spike and RNA-dependent-RNA polymerase (RdRp) genes of SARS-CoV-2 in Kerman, Iran.	0
187	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. **2023**, 14,	0
186	Artificial Intelligence: A Next-Level Approach in Confronting the COVID-19 Pandemic. **2023**, 11, 854	0
185	Understanding the Renin-Angiotensin System in Coronavirus Disease 2019. **2023**, 79-93	0

184	Motile cilia and microvillar: accomplices of SARS-CoV-2 in penetrating mucus barrier and infecting airway epithelium. **2023**, 8,	0
183	The origin and evolution of emerged swine acute diarrhea syndrome coronavirus with zoonotic potential. **2023**, 95,	0
182	SARS-CoV-2 and male infertility: from short- to long-term impacts.	0
181	Human Brain Microvascular Endothelial Cells Exposure to SARS-CoV-2 Leads to Inflammatory Activation through NF-Ƀ Non-Canonical Pathway and Mitochondrial Remodeling. **2023**, 15, 745	0
180	Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19. **2023**, 24, 5618	0
179	Pseudotyped Viruses for Coronaviruses. **2023**, 133-151	0
178	Genetic analysis of ACE2 peptidase domain in SARS-CoV-2-positive and SARS-CoV-2-negative individuals from Pakistan.	0
177	Pseudotyped Viruses. **2023**, 1-27	0
176	Murine Alveolar Macrophages Rapidly Accumulate Intranasally Administered SARS-CoV-2 Spike Protein leading to Neutrophil Recruitment and Damage.	0
175	Application of Pseudotyped Viruses. **2023**, 45-60	0
174	Getting in on the action: New tools to see SARS-CoV-2 infect a cell. **2023**, 30, 233-234	0
173	Advances in developing ACE2 derivatives against SARS-CoV-2. **2023**,	0
172	COVID-19: Pandemic Effect on Human Reproduction. **2023**, 3-15	0
171	Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. 14,	0
170	Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. **2023**, 11, 668	0
169	COVID-19 related liver injuries in pregnancy. 11, 1918-1929	0
168	At the crossroads of epidemiology and biology: Bridging the gap between SARS-CoV-2 viral strain properties and epidemic wave characteristics. **2023**,	0
167	Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice. **2023**, 11, 673	0

166	A comprehensive assessment of the antimicrobial and immunomodulatory effects of frequently consumed fermented foods: insights in the management of COVID-19. **2023**, 134,	0
165	Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors. **2023**, 63, 2158-2169	0
164	Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review. **2023**, 11, 929	0
163	Surface-modified biomaterials as disinfectants to combat viral infections: a SARS-COV-2 case study. **2023**, 147-169	0
162	The role of the bloodBrain barrier during neurological disease and infection.	0
161	Drug-induced liver injury in COVID-19 patients during hospitalization. **2023**, 102, e33294	0
160	Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial. **2023**, 18,	0
159	Early Transcriptional Responses of Human Nasal Epithelial Cells to Infection with Influenza A and SARS-CoV-2 Virus Differ and Are Influenced by Physiological Temperature. **2023**, 12, 480	0
158	Postmortem lung and heart examination of COVID-19 patients in a case series from Jordan. **2023**, 57, 102-112	0
157	COVID-19 Disease in Under-5 Children: Current Status and Strategies for Prevention including Vaccination. **2023**, 11, 693	0
156	Host Cell Targets for Unconventional Antivirals against RNA Viruses. **2023**, 15, 776	0
155	Bioactive Antimicrobial Peptides from Food Proteins: Perspectives and Challenges for Controlling Foodborne Pathogens. **2023**, 12, 477	0
154	The possible effects of COVID-19 on the human reproductive system. 1-7	0
153	Clinical Aspects Of Hypertensive Patients With COVID-19 Hospitalized In A Campaign Hospital In Northeast Brazil. **2023**, 36,	0
152	Extracellular Vesicles of COVID-19 Patients Reflect Inflammation, Thrombogenicity, and Disease Severity. **2023**, 24, 5918	0
151	Serum Angiotensin II as a Biomarker in COVID-19. **2023**, 917-940	0
150	Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives. **2023**, 0	0
149	Association of Cardiovascular Medications with Adverse Outcomes in a Matched Analysis of a National Cohort of Patients with COVID-19. **2023**, 100040	0

148	COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations. **2023**, 0	0
147	Canine Coronavirus Infection Modulates the Biogenesis and Composition of Cell-Derived Extracellular Vesicles. **2023**, 11, 976	0
146	Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?. 1-8	0
145	Reviews of drug candidates for COVID-19. 36, 219-226	0
144	Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids. **2023**, 20, 2276-2287	0
143	Many Roles of Carbohydrates: A Computational Spotlight on the Coronavirus S Protein Binding.	0
142	Myocarditis: causes, mechanisms, and evolving therapies. 1-14	0
141	Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.	0
140	Regulation of Epithelial Sodium Transport by SARS-CoV-2 Is Closely Related with Fibrinolytic System-Associated Proteins. **2023**, 13, 578	0
139	Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. **2023**, 14,	0
138	Impact of Drug Repurposing on SARS-Cov-2 Main Protease. **2022**, 96, 3311-3330	0
137	Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19. 14,	0
136	Unraveling the Underlying Molecular Mechanism of "Silent Hypoxia" in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. **2023**, 12, 2445	0
135	Multiscale network analysis identifies potential receptors for SARS-CoV -2 and reveals their tissue-specific and age-dependent expression.	0
134	Drugs for COVID-19 Treatment: A New Challenge.	0
133	Thymic tuft cells: potential "regulators" of non-mucosal tissue development and immune response.	0
132	Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. 14,	0
131	Multiple sclerosis and COVID-19 as two triggers of conjunctivitis: a case report. **2023**, 13, 17-19	0

130	Temporal pattern of humoral immune response in mild cases of COVID-19. 14, 40-51	0
129	Exploring the research landscape of COVID-19-induced olfactory dysfunction: A bibliometric study. 17,	0
128	Inhibition of Rab1B Impairs Trafficking and Maturation of SARS-CoV-2 Spike Protein. **2023**, 15, 824	0
127	COVID-19 Related Predisposition to Diabetic Ketoacidosis. **2023**,	0
126	Comprehensive review on the evolution of SARS-CoV-2(COVID-19): From emergence, outbreak,molecular characterization to the clinical challenges in designing and developing potential drugs, vaccines and therapies to counter SARSCoV-2. **2020**, 8, 43-48	0
125	Uncovering a link between COVID-19 and renal cell carcinoma.	0
124	Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. **2023**, 24, 6253	0
123	In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants. **2023**, 11, 736	0
122	Evaluation of Salivary Galectin-3 Level and its Potential Role in Increasing the Severity of COVID-19 Infection in Patients with Periodontitis. **2023**, 14, 3-8	0
121	Intestinal Damage, Inflammation and Microbiota Alteration during COVID-19 Infection. **2023**, 11, 1014	0
120	Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. **2023**, 17, 7017-7034	0
119	Epidemiological pattern of COVID-19 and its association with periodontal health in an urban Indian cohort. 11,	0
118	Autoimmune liver diseases and SARS-CoV-2. 29, 1838-1851	0
117	A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. **2023**, 13,	0
116	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. **2023**, 24, 6369	0
115	Association of ACE ID, MTHFR C677T, and MIF-173GC variants with the clinical course of COVID-19 patients. 1-15	0
114	In vitro studies of the renin-angiotensin system in human adipose tissue/adipocytes and possible relationship to SARS-CoV-2: a scoping review. **2023**, 12,	0
113	PM2 .5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway.	0

112	Enhancement of SARS-CoV-2 infection and growth by an ACE2-specific monoclonal antibody. **2023**, 95,	0
111	ACEI or not to ACEI: Review on using ACEI and ARBs on COVID-19 patients: Systemic review.	0
110	SARS-CoV-2 Receptors and Their Involvement in Cell Infection. **2023**, 17, 1-11	0
109	Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. **2023**, 107, 2983-2995	0
108	Transient loss and recovery of oral chemesthesis, taste and smell with COVID-19: a small case-control series.	0
107	Long COVID in autoimmune rheumatic diseases.	0
106	Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle.	0
105	The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling. **2023**, 11, 768	0
104	Interferon-lambda: New functions on intestinal symptoms in COVID-19. 29, 1942-1954	0
103	COVID-19 and preeclampsia: The unique and the mutually nonexclusive clinical manifestations. **2023**, 89,	0
102	Two Resveratrol Oligomers Inhibit Cathepsin L Activity to Suppress SARS-CoV-2 Entry. **2023**, 71, 5535-5546	0
101	Uncovering the Correlation between COVID-19 and Neurodegenerative Processes: Toward a New Approach Based on EEG Entropic Analysis. **2023**, 10, 435	0
100	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. 1-12	0
99	Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro). **2023**, 12, 519	0
98	Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). **2023**, 13, 4471	0
97	Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia.	0
96	Biomimetic SARS-CoV-2 Spike Protein Nanoparticles.	0
95	At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. **2023**, 28,	0

94	Determinants of species-specific utilization of ACE2 by human and animal coronaviruses.	0
93	Whole Sequencing and Detailed Analysis of SARS-CoV-2 Genomes in Southeast Spain: Identification of Recurrent Mutations in the 20E (EU1) Variant with Some Clinical Implications. **2023**, 11, 54	0
92	Persistence of SARS-CoV-2 Antigens in the Nasal Mucosa of Eight Patients with Inflammatory Rhinopathy for over 80 Days following Mild COVID-19 Diagnosis. **2023**, 15, 899	0
91	HLA Variation and SARS-CoV-2 Specific Antibody Response. **2023**, 15, 906	0
90	Effect some parameter of immunity CD4 and IL1 in Covid 19. **2023**,	0
89	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.	0
88	Molecular Understanding of ACE-2 and HLA-Conferred Differential Susceptibility to COVID-19: Host-Directed Insights Opening New Windows in COVID-19 Therapeutics. **2023**, 12, 2645	0
87	Cyanometabolites: molecules with immense antiviral potential. **2023**, 205,	0
86	Features of Liver Injury in COVID-19 Pathophysiological, Biological and Clinical Particularities. **2023**, 14, 156-169	0
85	Antiviral Activity of Cell Membrane-Bound Amphiphilic Polymers. **2023**, 39, 5408-5417	0
84	Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma. **2023**, 3,	0
83	Lymphocytes regulate expression of the SARS-CoV -2 cell entry factor ACE2 in the pancreas of T2DM patients.	0
82	Murine Coronavirus Disease 2019 Lethality Is Characterized by Lymphoid Depletion Associated with Suppressed Antigen-Presenting Cell Functionality. **2023**,	0
81	The evolution of SARS-CoV-2.	0
80	COVID-19 and the Cardiovascular System. **2024**, 137-158	0
79	Non-Hepatotropic Viral, Bacterial and Parasitic Infections of the Liver. **2024**, 448-526	0
78	Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection. **2023**, 14,	0
77	Lung Expression of Macrophage Markers CD68 and CD163, Angiotensin Converting Enzyme 2 (ACE2), and Caspase-3 in COVID-19. **2023**, 59, 714	0

76	SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19.	0
75	The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.	0
74	Repurposing immune boosting and anti-viral efficacy of Parkia bioactive entities as multi-target directed therapeutic approach for SARS-CoV-2: exploration of lead drugs by drug likeness, molecular docking and molecular dynamics simulation methods. 1-39	0
73	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. **2024**, 24-51	0
72	Oral Cavity and COVID-19: Clinical Manifestations, Pathology, and Dental Profession. **2024**, 173-190	0
71	COVID-19: Natural History and Spectrum of Disease. **2024**, 72-98	0
70	A Multiplexed SERS Microassay for Accurate Detection of SARS-CoV-2 and Variants of Concern.	0
69	Spatial Distribution of SARS-CoV-2 Receptors and Proteases in Testicular Cells. 002215542311689	0
68	Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines. **2023**, 20,	0
67	Revisiting the COVID-19 Pandemic: An Insight into Long-Term Post-COVID Complications and Repurposing of Drugs. **2023**, 3, 494-519	0
66	Assessment of the potential value of combining western medicine therapies with traditional chinese medicine in the treatment of COVID-19: Mechanistic perspectives. **2023**, 1-16	0
65	Development of a Peptide Sensor Derived from Human ACE2 for Fluorescence Polarization Assays of the SARS-CoV-2 Receptor Binding Domain. **2023**, 95, 6198-6202	0
64	A new tractable method for generating Human Alveolar Macrophage Like cells in vitro to study lung inflammatory processes and diseases.	0
63	Nano-Drug Delivery Systems for COVID-19 Drug Delivery. **2023**, 295-309	0
62	Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis. **2023**, 12, 1104	0
61	Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. **2023**, 106634	0
60	The Use of Azithromycin and Lopinavir-Ritonavir in the Treatment of COVID-19. **2023**, 339-360	0
59	Prospecting native and analogous peptides with anti-SARS-CoV-2 potential derived from the trypsin inhibitor purified from tamarind seeds. **2023**, 16, 104886	0

58	DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.	0
57	SARS-CoV-2 infection aggravates cigarette smoke-exposed cell damage in primary human airway epithelia. **2023**, 20,	0
56	Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support□free Days in Patients Hospitalized With COVID-19. **2023**, 329, 1183	0
55	Disrupted chromatin architecture in olfactory sensory neurons: looking for the link from COVID-19 infection to anosmia. **2023**, 13,	0
54	Modulation of in Vitro SARS-CoV-2 Infection by Stephania tetrandra and Its Alkaloid Constituents.	0
53	Comparative study between non-severe and severe Covid-19 infections in the levels of albumin, creatinine, and lactate dehydrogenase. **2023**,	0
52	Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. **2023**, 11, 1000	0
51	Correlation of covid-19 and Guillain-Barr□syndrome: A Mechanistic Perspective. **2023**, 100493	0
50	Association between soluble angiotensin-converting enzyme 2 in saliva and SARS-CoV-2 infection: a cross-sectional study. **2023**, 13,	0
49	Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147.	0
48	Genetic polymorphisms of ACE1, ACE2, IFTM3, TMPRSS2 and TNF□genes associated with susceptibility and severity of SARS-CoV-2 infection: a systematic review and meta-analysis.	0
47	Changes in intestinal morphology, number of mucus-producing cells and expression of coronavirus receptors APN, DPP4, ACE2 and TMPRSS2 in pigs with aging. **2023**, 54,	0
46	Portable Surface Plasmon Resonance Detector for COVID-19 Infection. **2023**, 23, 3946	0
45	Sphingosine Kinases Promote Ebola Virus Infection and Can Be Targeted to Inhibit Filoviruses, Coronaviruses, and Arenaviruses Using Late Endocytic Trafficking to Enter Cells.	0
44	Headache Features in Children and Adolescents with COVID-19. **2023**, 165-177	0
43	Seroprevalence of IgG and Subclasses against the Nucleocapsid of SARS-CoV-2 in Health Workers. **2023**, 15, 955	0
42	Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients. 29, 2283-2293	0
41	Immune-Mediated Neuropathies: Pathophysiology and Management. **2023**, 24, 7288	0

40	Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2.	0
39	The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. **2023**, 16, 175628482311655	0
38	Identification of Common Dysregulated Genes in COVID-19 and Hypersensitivity Pneumonitis: A Systems Biology and Machine Learning Approach.	0
37	Small molecules in the race of COVID-19 drug development. 1-22	0
36	RECAST: Study protocol for an observational study for the understanding of the increased REsilience of Children compared to Adults in SARS-CoV-2 infecTion. **2023**, 13, e065221	0
35	Gut distress and intervention via communications of SARS-CoV-2 with mucosal exposome. 11,	0
34	Infection routes, invasion mechanisms, and drug inhibition pathways of human coronaviruses on the nervous system. 17,	0
33	The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). **2023**, 43, 147-163	0
32	Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. **2023**, 105606	0
31	Human airway ex vivo models: new tools to study the airway epithelial cell response to SARS-CoV-2 infection.	0
30	Headaches associated with COVID-19. **2023**, 61-67	0
29	Features of the Immune Response in COVID-19. **2023**, 12, 122-129	0
28	A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. **2023**, 13,	0
27	Molecular networking-based drug repurposing strategies for SARS-CoV-2 infection by targeting alpha-1-antitrypsin (SERPINA1).	0
26	Role of macrophages in pulmonary arterial hypertension. 14,	0
25	COVID-19 and Obstructive Sleep Apnoea. **2023**, 231-243	0
24	Therapeutic strategies for COVID-19: progress and lessons learned.	0
23	Mice Humanized for MHC and hACE2 with High Permissiveness to SARS-CoV-2 Omicron Replication. **2023**, 105142	0

22	Biogenic Zinc Oxide Nanoparticles and Their Biomedical Applications: A Review.	0
21	Home-based exercise alters pulmonary function and cellular stress markers in overweight middle-aged men during covid-19 Home quarantine. **2023**, 15,	0
20	COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations. 15, 441-459	0
19	Routine placental histopathology findings from women testing positive for SARS-CoV -2 during pregnancy: Retrospective cohort comparative study.	0
18	Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.	0
17	Statistical analysis and data visualization of Indonesia and Malaysia SARS Cov-2 metadata. **2023**,	0
16	Diabetes mellitus in relation to COVID-19. **2023**, 77-89	0
15	Biochemical, inflammatory and oxidative stress biomarkers in obese patients after COVID-19.	0
14	SARS-CoV-2 Enters Human Leydig Cells and Affects Testosterone Production In Vitro. **2023**, 12, 1198	0
13	Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID -19: A retrospective single-center experience.	0
12	Nebulizer spray delivery of phytopharmaceutical nanosuspension via oral and nasal route. **2023**, 437-457	0
11	MicroRNAs and COVID-19. **2023**, 109-122	0
10	Dietary intervention with functional foods modulating gut microbiota for improving the efficacy of COVID-19 vaccines. **2023**, e15668	0
9	Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2. **2023**,	0
8	Novel insight into the underlying dysregulation mechanisms of immune cell-to-cell communication by analyzing multitissue single-cell atlas of two COVID-19 patients. **2023**, 14,	0
7	Spatiotemporal transcriptome atlas of human embryos after gastrulation.	0
6	SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues. 14,	0
5	Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice. **2023**, 116, 154858	0

4	Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2. **2023**, 4,	0
3	Cigarette smoke increases susceptibility of alveolar macrophages to SARS-CoV-2 infection through inducing reactive oxygen species-upregulated angiotensin-converting enzyme 2 expression. **2023**, 13,	0
2	Nanotechnologies for the Diagnosis and Treatment of SARS-CoV-2 and Its Variants.	0
1	Gastrointestinal manifestations of long-term effects after COVID-19 infection in patients with dialysis or kidney transplantation: An observational cohort study. 29, 3013-3026	0